

Attorney Docket No.: 0168.00106

Express Mail No.: EL 818 071 242 US

## **SEQUENCE CHARACTERISTICS OF BLADDER CANCER**

### **CROSS-REFERENCE TO RELATED APPLICATIONS**

The present application claims the benefit of priority to PCT application PCT/US00/41005, filed September 27, 2000, which claims the benefit of priority under 35 U.S.C. §119(e) of U.S. Provisional Patent Application Number 60/156,153, filed September 27, 1999, both of which are incorporated herein by reference.

### **BACKGROUND OF THE INVENTION**

#### **FIELD OF THE INVENTION**

The present invention relates to the identification of polynucleotide sequences that are differentially expressed in bladder cancer. More specifically, the present invention relates to the use of the sequences and gene products for diagnosis and as probes.

#### **DESCRIPTION OF RELATED ART**

Bladder cancer is the second most-common genitourinary cancer in the United States, with only prostate cancer being more frequently diagnosed. Bladder cancer accounts for approximately two percent of all malignant tumors and approximately seven percent of all urinary tract malignancies in U.S. men. Over 54,000 new cases were estimated to be diagnosed in the United States in 1998, with approximately 12,500 deaths predicted [American Cancer Society, 1998]. The prevalence of bladder cancer is higher in industrialized nations, perhaps reflecting increased exposure to environmental carcinogens. Men are three times more frequently affected than women. The disease usually occurs between 60-70 years of age and the age-adjusted bladder cancer rate in white men is almost twice that of black men. Most bladder cancers (over 90%) are carcinomas of the transitional epithelium of the bladder's mucosal lining (transitional cell carcinoma (TCC)). Although 90 percent of the cases are localized at diagnosis, up to 80 percent recur.

A number of etiological factors are associated with the development of bladder cancer, but in industrialized countries, cigarette smoking is the most significant. Specific chemicals have also been identified as causing bladder cancer, as have a number of occupational exposures to less well-defined specific agents. Treatment with cytostatic drugs, especially cyclophosphamide, is associated with increased risk of bladder cancer, as is treatment with radiotherapy for uterine cancer.

Bladder cancer is a potentially preventable disease, with a significant morbidity and mortality in many parts of the world.

Tumors are graded according to the degree of cellular abnormality, with the most atypical cells being designated as high-grade (i.e., G3 grade) tumors. The major prognostic factors in carcinoma of the bladder are the depth of invasion into the bladder wall and the degree of differentiation of the tumor. The higher the grade of the tumor at the diagnosis, the higher the incidence of death from the disease within two years.

The stage of development of the tumor is significant in estimating disease prognosis. Most superficial, non-invasive tumors are papillary tumors which do not invade the *lamina propria*, and are classified as non-invasive TCC, i.e., "Ta" tumors, and they can recur, but nearly 70% will not progress further. A tumor which does not invade the muscle but does enter the *lamina propria* presents in many cases a worse prognosis. Such tumors are also classified as non-invasive TCC but are termed T1 tumors. Most superficial tumors are well differentiated and classified as G1 grade tumors. Patients in whom superficial tumors are less differentiated, large, multiple, or associated with carcinoma *in situ* in other areas of the bladder mucosa, (classified as G2-G3 tumors) are at greatest risk for recurrence and the development of invasive cancer. Invasive bladder tumors tend to spread rapidly to the regional lymph nodes and then into adjacent structures. Overall, the five-year survival rate of TCC is 76 percent for whites and 55 percent for blacks.

One of the management problems is the fact that carcinoma of the bladder is frequently multifocal. The entire bladder epithelium and the lining of the entire urothelial cell tract can undergo malignant change. After apparently successful treatment of a bladder lesion, new tumors can occur at the same site (recurrence) or in other urothelial cells in the bladder. Approximately 30 percent of bladder carcinomas present as multiple lesions at the time of initial diagnosis. The early diagnosis of bladder cancer is central to the effective treatment of TCC. Presently, the detection of bladder tumors relies on intravenous pyelogram or other contrast studies to rule out urothelial involvement in the kidneys or ureters, and invariably cystoscopy which remains the accepted standard for diagnosis of mucosal abnormalities. There are no presently reliable methods available to easily and specifically identify the presence of bladder cancer cells. A variety of new technologies and potential tumor markers are being studied in bladder cancer and some are being translated into clinical use.

It is important to realize that all available results of the diagnostic value of tumor markers do not allow firm clinical recommendations, but tests based on biomarkers undoubtedly influence the management of bladder cancer in the near future. Several new markers have been already identified and even approved for use (e.g. bladder tumor antigen (BTA) markers, NMP22, FDP). However, their clinical use is limited [Grossman, 1998], due to sensitivity and specificity problems in conjunction with cystoscopic examination.

Furthermore, due to the high rate of disease recurrence, follow-up of TCC patients is obligatory. There is a need to eliminate the invasive cystoscopy method of diagnosis and of follow-up and replace it with a reliable and non-invasive method of diagnosis.

Approximately 70-80 percent of patients with newly diagnosed bladder cancer present with superficial, non-invasive bladder tumors. Those who do are often curable. Tumor patients with deeply invasive disease can sometimes be cured by complete surgical removal of the bladder, irradiation, or a combination of modalities that include chemotherapy, however the five-year survival rate is less likely for such tumors. It is therefore of major importance to detect new tools that aid in both the initial early diagnosis and in follow-up of non-invasive TCC tumors.

Adverse prognostic features associated with a greater risk of disease progression include the presence of multiple aneuploid cell lines, nuclear p53 overexpression, and expression of the Lewis-x blood group antigen [Hudson and Herr, 1995; Lacombe et al., 1996]. It has been postulated that p53 can be useful for predicting the level of aggression of the tumor and to identify patients who will not benefit from chemotherapy. However, only a very small, select group of patients with invasive disease can benefit from this approach [Ozen, 1998]. Several treatment methods (i.e., transurethral surgery, intravesical medications, and cystectomy) have been used in the management of patients with superficial

tumors, and each method can be associated with five-year survival in 55-80 percent of patients treated [Hudson and Herr, 1995; Torti and Lum, 1984]. Invasive tumors that are confined to the bladder muscle on pathologic staging after radical cystectomy are associated with an approximately 75 percent, five-year progression-free rate of survival. Patients with more deeply invasive tumors (which are also usually less well differentiated) experience five-year survival rates of 20-40 percent following radical cystectomy. When the patient presents with a locally extensive tumor that invades pelvic viscera or with metastases to lymph nodes or distant sites, a five-year survival rate is uncommon, but considerable symptomatic palliation can still be achieved.

Surgery is the main treatment method. The extent of surgery is dependent on the pathological stage of the disease. Early disease is generally treated by intravesical chemotherapy and transurethral resection. Locally invasive disease can usually be managed only by radical cystectomy and urinary diversion. Definitive (curative) radiotherapy is generally reserved for bladder cancer patients who are not candidates for surgery. For superficial, low-grade disease, chemotherapy is applied intravesically (directly into the bladder) to concentrate the drug at the tumor site and eliminate any residual tumor mass after resection. Systemic chemotherapy can also be used to manage advanced bladder cancer; complete response rates of 30-50 percent have been reported. Single agent chemotherapy has demonstrated limited success.

However, even following surgery and resection of non-invasive TCC tumors, frequent follow-up is required (every 3 months) in both non-invasive and invasive cases.

It would therefore be useful to be able to identify early stage TCC in bladder cancer which has a significantly higher cure rate and generally does not require surgery. In addition, it would be useful to identify markers that can be employed for early diagnosis and follow-up of both non-invasive and invasive TCC, as an efficient and non-invasive alternative to cytoscopy.

## **SUMMARY OF THE INVENTION**

According to the present invention, there is provided a method of diagnosing the presence of bladder cancer in a patient by analyzing a patient-derived sample for the presence of a least one expressed gene wherein the high level of expression of the gene is indicative of bladder cancer. Also provided by the present invention is a polynucleotide sequence whose expression is indicative of bladder cancer. A marker for bladder cancer is also provided. There are also provided methods of diagnosing bladder cancer by screening for the presence of at least one expressed gene wherein the presence of the expressed gene is indicative of bladder cancer. Methods of treating and regulating bladder cancer-associated pathology by administering to a patient a therapeutically effective amount of a chemical compound which inhibits a gene

comprising the nucleic acids sequences of the present invention are also provided.

## DESCRIPTION OF THE INVENTION

According to the present invention, purified, isolated and cloned nucleic acid sequences associated with bladder cancer are provided. More specifically, the polynucleotides of the present invention are described in Tables 1, 2, and 5 and the corresponding sequences are set forth in Tables 3, 4 and 6 respectively.

When referring to bladder cancer, both invasive and noninvasive forms are included. Bladder cancers can also be referred to as transitional cell carcinomas or "TCC".

The present invention further provides a method of diagnosing the presence of bladder cancer in a patient, including the steps of analyzing a tissue sample from the patient for the presence of at least one expressed gene (up-regulated) wherein the mRNA from the expressed gene hybridizes to at least one of the sequences in Tables 1 or 2, with hybridization occurring under conditions sufficiently stringent to require at least 95% base pairing.

Further the present invention provides antibodies directed against the gene products of the sequences of the present invention. The antibodies can be either monoclonal, polyclonal or recombinant and be used in immunoassays as described in the Methods herein below.



By regulate or modulate or control is meant that the process is either induced or inhibited to the degree necessary to effect a change in the process and the associated disease state in the patient. Whether induction or inhibition is being contemplated is apparent from the process and disease being treated and is known to those skilled in the medical arts. The present invention identifies genes for gene therapy, diagnostics and therapeutics that have direct causal relationships between a disease and its related pathologies and up- or down-regulator (responder) genes. That is, the present invention is initiated by a physiological relationship between cause and effect.

The present invention identifies polynucleotides named in Tables 1 and 2, and set forth in Tables 3 and 4 respectively, that can be utilized diagnostically in bladder cancer. Polynucleotides named in Table 1 were found to match sequences in data banks and were newly found in the present application to be upregulated in TCC. The polynucleotides named in Table 2 are either genes with unknown protein product or of unknown genes. All the polynucleotides named in both Tables 1 and 2 were found to be associated with TCC relative to normal bladder samples. The polynucleotides named in Table 5 have their corresponding sequences set forth in Table 6, some of which are novel.

Where the sequences are partial sequences, they are markers or probes for genes that are regulated in bladder carcinoma. By "regulated" it is meant that the genes can be either upregulated or downregulated, depending upon the specific gene. In general these partial sequences are designated

"Expressed Sequence Tags" (ESTs) and are markers for the genes actually expressed *in vivo* and are ascertained as described herein. Generally, ESTs comprise DNA sequences corresponding to a portion of nuclear encoded mRNA. The EST has a length that allows for PCR (polymerase chain reaction), use as a hybridization probe and is a unique designation for the gene with which it hybridizes (generally under conditions sufficiently stringent to require at least 95% base pairing).

For a detailed description and review of ESTs and their functional utility see WO 93/00353 which is incorporated in its entirety by reference. WO 93/00353 further describes how the EST sequences can be used to identify the transcribed genes. The Example herein also describes a method of identification. The present invention also provides a method of diagnosing the presence of bladder cancer in a patient, by the expression of at least one expressed gene (up-regulated) identified by the polynucleotides of the present invention set forth in Tables 1-6. Methods of identification of hybridization results can include, but are not limited to, immunohistochemical staining of the tissue samples. Further for identification of the gene, *in situ* hybridization, Southern blotting, single strand conformational polymorphism (SSCP), restriction endonuclease fingerprinting (REF), PCR amplification and DNA-chip analysis using nucleic acid sequence of the present invention as probes/primers can be used.

The present invention further provides proteins encoded by the identified genes. The present invention further provides antibodies directed against these proteins. The present invention further provides transgenic animals

and cell lines carrying at least one expressible gene identified by the present invention. The present invention further provides knock-out eukaryotic organisms in which at least one nucleic acid sequences as identified by the probes of the present invention and prepared as described in the Methods.

The present invention provides a method of diagnosing bladder cancer, in particular TCC, in a subject which comprises determining in a sample from the subject the level of expression of at least one polypeptide –encoding polynucleotide, wherein a higher level of expression of the polynucleotide compared to the level of expression of the polynucleotide in a subject free of bladder cancer is indicative of bladder cancer, and wherein the polypeptide – encoding polynucleotide comprises a polynucleotide selected from the group consisting of

- (a) the polynucleotides listed in Tables 3, 4 and 6;
- (b) polynucleotides having sequences that differ from the polynucleotides in (a), without changing the polypeptide encoded thereby; and
- (c) polynucleotides which are at least 70% homologous to the polynucleotides of (a).

In a preferred method of the invention, the analyzing step comprises using mRNA from the expressed gene to hybridize to at least one of the sequences in Tables 3, 4 and 6. In other preferred methods of the invention, the analyzing step comprises using RT-PCR technology or using a specific antibody to detect the presence of a polypeptide encoded by said polynucleotide.

The present invention also provides a method of diagnosing of diagnosing stage Ta or stage T1 in TCC, which comprises determining in a sample from the patient the level of expression of at least one polypeptide –encoding polynucleotide, wherein a higher level of expression of the polynucleotide compared to the level of expression of the polynucleotide in a patient free of bladder cancer is indicative of stage Ta or stage T1, and wherein the polypeptide –encoding polynucleotide comprises a polynucleotide selected from the group consisting of

- (a) the polynucleotides listed in Tables 3, 4 and 6;
- (b) polynucleotides having sequences that differ from the polynucleotides in (a), without changing the polypeptide encoded thereby; and
- (c) polynucleotides which are at least 70% homologous to the polynucleotides of (a).

The present invention also provides isolated polynucleotides which comprise a polynucleotide selected from the group consisting of:

- (a) the novel polynucleotides listed in Tables 4 and 6;
- (b) polynucleotides having sequences that differ from the polynucleotides in (a), without changing the polypeptide encoded thereby; and
- (c) polynucleotides which are at least 70% homologous to the polynucleotides of (a).

The present invention also provides such polynucleotides wherein the polynucleotide comprises a polynucleotide having at least 30, preferably at least 40, nucleotides from the polynucleotides described above.

The present invention also provides compositions comprising the isolated polynucleotides of the invention.

The present invention also provides an isolated polypeptide encoded by a polynucleotide, wherein the polynucleotide comprises a polynucleotide selected from the group consisting of:

(a) the polynucleotides listed in Tables 3, 4 and 6;

(b) polynucleotides having sequences that differ from the polynucleotides in (a), without changing the polypeptide encoded thereby; and

(c) polynucleotides which are at least 70% homologous to the polynucleotides of (a).

The present invention also provides such a polypeptide, wherein the polypeptide is a portion which retains the biological activity thereof or a polypeptide which is at least substantially homologous or identical thereto.

The present invention also provides a peptide, wherein the peptide is dominant negative peptide which competes with the biological activity of the polypeptide.

The present invention also provides an antibody which binds to a unique epitope of the polypeptide of the invention. The present invention also provides a method of diagnosing bladder cancer in a patient which comprises determining in a sample from the patient the level of expression of at least one polypeptide, wherein a higher level of polypeptide compared to the level of the polypeptide in a patient free of bladder cancer is indicative of bladder cancer.

The method includes using an antibody, preferably wherein the presence of more than one polypeptide is detected by using more than one such antibody. The present invention also provides a method of treating bladder cancer-associated pathology in a subject by administering to the subject a therapeutically effective amount of a chemical compound which inhibits a gene, or polypeptide encoded thereby, which comprises a polynucleotide selected from the group consisting of:

- (a) the polynucleotides listed in Tables 3, 4 and 6;
- (b) polynucleotides having sequences that differ from the polynucleotides in (a), without changing the polypeptide encoded thereby; and
- (c) polynucleotides which are at least 70% homologous to the polynucleotides of (a).

The present invention also provides a gene therapy vehicle for delivering a polynucleotide of the invention to a subject, whereby the polynucleotide is expressed in the target cells of the subject. The present invention also provides isolated antisense oligonucleotides complementary to the polynucleotides of the invention.

The samples from the subjects which are used for diagnosis comprise samples of urine, blood, saliva, tissues and cells of all types; urine samples are preferred. A control sample includes a normal equivalent sample derived from a healthy subject.

The term "antibody" includes polyclonal antibody, single chain antibody, Fab fragment, monoclonal (MAB), polyclonal and recombinant

antibodies. A molecule which comprises the antigen-binding portion (CDR) of an antibody specific for a polypeptide, variant or fragment is also included in the term "antibody".

Negative dominant peptide refers to a partial cDNA sequence that encodes for a part of a protein, i.e. a peptide (see Herskowitz, 1987). This peptide can have a different function from the protein from which it was derived. It can interact with the full protein and inhibit its activity or it can interact with other proteins and inhibit their activity in response to the full protein. Negative dominant means that the peptide is able to overcome the natural proteins and fully inhibit their activity to give the cell a different characteristic, like resistance or sensitization to killing. For therapeutic intervention either the peptide itself is delivered as the active ingredient of a pharmaceutical composition or the cDNA can be delivered to the cell utilizing the same methods as for antisense delivery.

The antagonist or regulating agent or active ingredient is dosed and delivered in a pharmaceutically acceptable carrier as described herein below. The term antagonist or antagonizing is used in its broadest sense. Antagonism can include any mechanism or treatment which results in inhibition, inactivation, blocking or reduction in gene activity or gene product and for example preventing progression from non-invasive to invasive. The antagonizing step can include blocking cellular receptors for the gene products and can include antisense treatment as discussed herein.

Many reviews have covered the main aspects of antisense (AS) technology and its enormous therapeutic potential (Wright and Anazodo, 1995).

There are reviews on the chemical (Crooke, 1995; Uhlmann *et al*, 1990), cellular.. (Wagner, 1994) and therapeutic (Hanania, *et al*, 1995; Scanlon, *et al*, 1995; Gewirtz, 1993) aspects of this rapidly developing technology. Antisense intervention in the expression of specific genes can be achieved by the use of synthetic AS oligonucleotide sequences (for recent reports see Lefebvre-d'Hellencourt *et al*, 1995; Agrawal, 1996; Lev-Lehman *et al*, 1997). AS oligonucleotide sequences can be short sequences of DNA, typically 15-30 mer but can be as small as 7 mer (Wagner *et al*, 1996), designed to complement a target mRNA of interest and form an RNA:AS duplex. (See also Calabretta *et al*, 1996). Phosphorothioate antisense oligonucleotides do not normally show significant toxicity at concentrations that are effective, exhibit sufficient pharmacodynamic half-lives in animals (Agarwal *et al.*, 1996) and are nuclease resistant. Instead of an antisense sequences as discussed herein above, ribozymes can be utilized. This is particularly necessary in cases where antisense therapy is limited by stoichiometric considerations (Sarver *et al.*, 1990, *Gene Regulation and Aids*, pp. 305-325).. (See also Hampel and Tritz, 1989; Uhlenbeck, 1987).

Ribozymes catalyze the phosphodiester bond cleavage of RNA. Several ribozyme structural families have been identified including Group I introns, RNase P, the hepatitis delta virus ribozyme, hammerhead ribozymes and the hairpin ribozyme (Sullivan, 1994; U.S. Patent No. 5,225,347, columns 4-5). Modifications or analogues of nucleotides can be introduced to improve the



therapeutic properties of the nucleotides. Improved properties include increased nuclease resistance and/or increased ability to permeate cell membranes:

Nuclease resistance, where needed, is provided by any method known in the art that does not interfere with biological activity of the antisense oligodeoxy-nucleotides, cDNA and/or ribozymes as needed for the method of use and delivery (Iyer et al., 1990; Eckstein, 1985; Spitzer and Eckstein, 1988; Woolf et al., 1990; Shaw et al., 1991). Modifications that can be made to oligonucleotides in order to enhance nuclease resistance include, but are not limited to, modifying the phosphorous or oxygen heteroatom in the phosphate backbone. These modifications also include preparing methyl phosphonates, phosphorothioates, phosphorodithioates and morpholino oligomers.

The present invention also includes all analogues of, or modifications to, an oligonucleotide or polynucleotide of the invention that does not substantially affect the function of the oligonucleotide. The nucleotides can be selected from naturally occurring or synthetic modified bases. Naturally occurring bases include adenine, guanine, cytosine, thymine and uracil. Modified bases of the oligonucleotides include xanthine, hypoxanthine, 2-aminoadenine, 6-methyl, 2-propyl and other alkyl adenines, 5-halo uracil, 5-halo cytosine, 6-aza cytosine and 6-aza thymine, pseudo uracil, 4-thiuracil, 8-halo adenine, 8-aminoadenine, 8-thiol adenine, 8-thiolalkyl adenines, 8-hydroxyl adenine and other 8-substituted adenines, 8-halo guanines, 8-amino guanine, 8-thiol guanine, 8-thioalkyl guanines, 8-hydroxyl guanine and other substituted guanines, other

aza and deaza adenines, other aza and deaza guanines, 5-trifluoromethyl uracil and 5-trifluoro cytosine.

In addition, analogues of nucleotides and/or polynucleotides can be prepared wherein the structure of the nucleotide and/or polynucleotide is fundamentally altered and that are better suited as therapeutic or experimental reagents. An example of a nucleotide analogue is a peptide nucleic acid (PNA) wherein the deoxyribose (or ribose) phosphate backbone in DNA (or RNA) is replaced with a polyamide backbone which is similar to that found in peptides. PNA analogues have been shown to be resistant to degradation by enzymes and to have extended lives *in vivo* and *in vitro*. Further, PNAs have been shown to bind stronger to a complementary DNA sequence than a DNA molecule. This observation is attributed to the lack of charge repulsion between the PNA strand and the DNA strand. Other modifications that can be made to oligonucleotides include polymer backbones, cyclic backbones, or acyclic backbones.

The active ingredients of pharmaceutical compositions can include oligonucleotides that are nuclease resistant as are needed for the practice of the invention or a fragment thereof shown to have the same effect when targeted against the appropriate sequence(s) and/or ribozymes. Combinations of active ingredients as disclosed in the present invention can be used, including combinations of antisense sequences.

The antisense oligonucleotides (and/or ribozymes) and cDNA of the present invention can be synthesized by any method known in the art for ribonucleic or deoxyribonucleic nucleotides. For example, an Applied Biosystems

380B DNA synthesizer can be used. When fragments are used, two or more such sequences can be synthesized and linked together for use in the present invention.

The nucleotide sequences of the present invention can be delivered either directly or with viral or non-viral vectors. When delivered directly the sequences are generally rendered nuclease resistant. Alternatively the sequences can be incorporated into expression cassettes or constructs such that the sequence is expressed in the cell as discussed herein below. Generally the construct contains the proper regulatory sequence or promotor to allow the sequence to be expressed in the targeted cell.

The proteins of the present invention can be produced recombinantly (see generally Marshak et al, 1996 "Strategies for Protein Purification and Characterization. A laboratory course manual.", CSHL Press) and analogues can be due to post-translational processing. More in particular, with respect to polynucleotides disclosed herein, and corresponding polypeptides expressed from them, the invention further comprehends isolated and/or purified polynucleotides (nucleic acid molecules) and isolated and/or purified polypeptides having at least about 70%, preferably at least about 75% homology, more preferably at least about 80%, even more preferably at least about 90%, most preferably at least about 95% homology to the polynucleotides and polypeptides disclosed herein.

Nucleotide sequence homology can be determined using the "Align" program of Myers and Miller, ((1988) CABIOS 4:11-17) and available at

NCBI. Alternatively or additionally, the term "homology" , for instance, with respect to a nucleotide or amino acid sequence, can indicate a quantitative measure of homology between two sequences. The percent sequence homology can be calculated as  $(N_{ref} - N_{dif}) * 100 / N_{ref}$  , wherein  $N_{dif}$  is the total number of non-identical residues in the two sequences when aligned and wherein  $N_{ref}$  is the number of residues in one of the sequences. Hence, the DNA sequence AGTCAGTC has a sequence similarity of 75% to AATCAATC ( $N_{ref} = 8$ ;  $N_{dif} = 2$ ).

Alternatively or additionally, "homology" with respect to sequences can refer to the number of positions with identical nucleotides or amino acid residues divided by the number of nucleotides or amino acid residues in the shorter of the two sequences wherein alignment of the two sequences can be determined in accordance with the Wilbur and Lipman algorithm ((1983) Proc. Natl. Acad. Sci. USA 80:726), for instance, using a window size of 20 nucleotides, a word length of 4 nucleotides, and a gap penalty of 4, and computer-assisted analysis and interpretation of the sequence data including alignment can be conveniently performed using commercially available programs (e.g., Intelligenetics™ Suite, Intelligenetics Inc., CA). When RNA sequences are said to be similar, or to have a degree of sequence identity or homology with DNA sequences, thymidine (T) in the DNA sequence is considered equal to uracil (U) in the RNA sequence . RNA sequences within the scope of the invention can be derived from DNA sequences or their complements, by substituting thymidine (T) in the DNA sequence with uracil (U).

Additionally or alternatively, amino acid sequence similarity or identity or homology can be determined, for instance, using the BlastP program (Altschul et al. Nucl. Acids Res. 25:3389-3402) and available at NCBI. The following references provide algorithms for comparing the relative percentage homology of amino acid residues of two proteins, and additionally, or alternatively, with respect to the foregoing, the teachings in these references can be used for determining percent homology: Smith et al. (1981) Adv. Appl. Math. 2:482-489; Smith et al. (1983) Nucl. Acids Res. 11:2205-2220; Devereux et al. (1984) Nucl. Acids Res. 12:387-395; Feng et al. (1987) J. Molec. Evol. 25:351-360; Higgins et al. (1989) CABIOS 5:151-153; and Thompson et al. (1994) Nucl. Acids Res. 22:4673-480.

Polynucleotide sequences that are complementary to any of the sequences or fragments encompassed by the present invention discussed above are also considered to be part of the present invention. Whenever any of the sequences discussed above are produced in a cell, the complementary sequence is concomitantly produced and, thus, the complementary sequence can also be used as a probe for the same diagnostic purposes.

"Functionally relevant" refers to the biological property of the molecule and in this context means an *in vivo* effector or antigenic function or activity that is directly or indirectly performed by a naturally occurring protein or nucleic acid molecule. Effector functions include, but are not limited to include, receptor binding, any enzymatic activity or enzyme modulatory activity, any carrier binding activity, any hormonal activity, any activity in promoting or inhibiting adhesion of cells to

extracellular matrix or cell surface molecules, or any structural role as well as having the nucleic acid sequence encode functional protein and can be expressible. The antigenic functions essentially mean the possession of an epitope or antigenic site that is capable of cross-reacting with antibodies raised against a naturally occurring protein. Biologically active analogues share an effector function of the native which can, but do not necessarily, additionally possess an antigenic function.

The above discussion provides a factual basis for the use of the sequences of the present invention to identify bladder cancer-associated genes and provide diagnostic probes and markers to identify bladder cancer, particularly in the early stages of TCC.

## **EXAMPLES**

### **EXAMPLE 1**

#### **METHODS OF THE INVENTION**

A detailed description of the methods employed in the present invention is set forth in co-assigned US patent application USSN 09/534,661 filed on March 24, 2000, corresponding to PCT patent publication number WO 00/56935 and incorporated herein by reference in its entirety. The method includes preparing cell fractionations; extracting intact total RNA from membrane bound polysomes and free polysomes; preparing cDNA probes from template RNA derived from the extracted polysomes; performing microarray-based

comparison of the relative abundance of the different RNA species; analyzing the results; thereby identifying genes or clones encoding specifically membranal or secreted proteins.

Identification of cDNAs and genes encoding secreted or membranal encoding mRNAs is of major importance in TCC. More specifically, novel genes which mark the early stages of TCC and code for secreted proteins are the ultimate markers for diagnosis and follow-up of TCC. By deriving probes from template RNA extracted from membrane-bound polysomes and free polysomes and performing microarray-based comparison of the relative abundance of different RNA species, such potentially secreted proteins can be identified. Analysis of the results of such comparison and identification of the clones encoding for membranal or secreted proteins provides a valuable tool which can be used together with other gene discovery tools, and which in itself enables identification of likely targets for drug development.

Since membranal and secreted proteins are both accessible and critical for transduction of numerous intra- and intercellular signals, they are generally viewed as preferred targets for pharmacological use and intervention. Therefore, the *a priori* classification of arrayed unknown gene sequences into those that potentially code for secreted and membranal proteins is of great value for the optimization of a high-throughput process of identifying potential drug targets. Furthermore, the identification of genes which express membranal or secreted proteins that are differentially expressed in different cellular situations is of the utmost importance in designing therapeutic or diagnostic tools for TCC.

A method of identifying clones which encode membranal and secreted proteins was employed by preparing bladder cancer cell fractionations, preparing cDNA probes from template RNA derived from membrane-bound polysomes and free-polysomes, performing a microarray-based comparison of the relative abundance of different RNA species, analyzing the results and thereby identifying genes encoding for membranal and secreted proteins. Since membranal and secreted proteins are generally viewed as preferred targets for pharmacological intervention, the present invention thus provides a method of identifying likely targets for TCC diagnosis and therapy.

#### HYBRIDIZATION AND PROBES:

##### TCC and normal bladder hybridization:

The probes were prepared from normal healthy bladder samples and from TCC tumors. Only intact RNA with a proper histological report indicating the existence of TCC was used. All normal and tumor material was collected from two separate clinical centers. Such approach minimizes the influence of local specific surgical bias or subjectivity of the pathological report. Forty-one hybridizations were performed. In each hybridization, two probes were used simultaneously, each labeled with either Cy3 or Cy5.

These probes were as follows: Probe 1. Probe 1 was common to all hybridizations (common control probe). RNA from TCC samples was mixed with RNA from normal bladder samples. An equal amount of the RNA mixture was labeled with Cy3 and used in all hybridizations; and Probe 2. In each of the



hybridizations, a different RNA sample from a single donor was used (test probe).

A common control for all the hybridizations enables comparison of the results between the different hybridizations. If the common control (probe 1) hybridization results are similar in pattern in different hybridizations, comparison can be made between the results of probe 2 hybridizations and all hybridizations. Seventeen hybridizations included 16 RNA samples extracted from different control healthy bladder mucosa labeled with Cy5. Twenty-three hybridizations were performed with RNA samples derived from tumor tissues, either from non-invasive Ta or from T1 stages of development. Two hybridizations were performed with RNA extracted from 2 invasive TCC samples.

The hybridizations were carried out in three separate sets, but the same common control was used in all sets. Set 1 includes hybridizations 2-11 (TC2-TC11), set 2 includes hybridizations 16-25 (TC16-TC25), and set 3 includes hybridizations 28-41 (TC28-TC41). By using three different sets of hybridizations, the possibility of technical effects related to specific hybridizations is reduced. See Tables below and related description.

#### Probe from annotation of potentially secreted proteins:

TCC cell line -T24- (from ATCC) was used for cellular fractionation. Membrane-bound polysomes were separated from free polysomes using a sucrose step gradient. RNA coding for potentially secreted proteins was isolated

from this microsomal-membranal fraction and separated from RNA coding for intracellular proteins. Hybridization was performed as described hereunder.

The probes used were as follows: Probe 1. Free polysomal RNA fraction labeled with Cy3; and Probe 2. Membrane-bound RNA fraction with Cy5.

### TCC CHIP PREPARATION

All hybridizations were performed on TCC designated microarray.

The microarray was made up of cDNA clones derived from 3 different libraries:

SDGI library: (Described in co-assigned US Patent Application USSN 09/538,709, filed 30 March, 2000, corresponding to PCT application filed March, 2001 and incorporated herein by reference in its entirety): A pool of non-invasive TCC, invasive TCC and normal bladder was used for library preparation. 4550 clones from the SDGI library were included in the TCC chip.

Antisense library: (Described in co-assigned US Provisional Patent Application SN 60/157,843, filed 6 October, 1999, corresponding to PCT application PCT/US00/27557, filed 6 October, 2000, and incorporated herein by reference in its entirety): The same cDNA pool used for the SDGI library was used for the preparation of a library enriched for antisense sequences. 450 clones from this library were included in the TCC chip.

SSH library: (Diatchenko et al., 1996). A subtraction library was made as follows. A normal bladder RNA pool was used for subtraction from non-invasive TCC RNA pool. The subtracted cDNA was used for the microarray printing. 5000 clones from the SSH library were used for printing.

General methods in molecular biology:

Standard molecular biology techniques known in the art and not specifically described were generally followed as in Sambrook et al., *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Laboratory Press, New York (1989), and in Ausubel et al., *Current Protocols in Molecular Biology*, John Wiley and Sons, Baltimore, Maryland (1989) and in Perbal, *A Practical Guide to Molecular Cloning*, John Wiley & Sons, New York (1988), and in Watson et al., *Recombinant DNA*, Scientific American Books, New York and in Birren et al (eds) *Genome Analysis: A Laboratory Manual Series, Vols. 1-4* Cold Spring Harbor Laboratory Press, New York (1998) and methodology as set forth in United States patents 4,666,828; 4,683,202; 4,801,531; 5,192,659 and 5,272,057 and incorporated herein by reference. Polymerase chain reaction (PCR) was carried out generally as in *PCR Protocols: A Guide To Methods And Applications*, Academic Press, San Diego, CA (1990). In-situ (In-cell) PCR in combination with Flow Cytometry can be used for detection of cells containing specific DNA and mRNA sequences (Testoni et al, 1996, Blood 87:3822.)

General methods in immunology: Standard methods in immunology known in the art and not specifically described are generally followed as in Stites et al.(eds), *Basic and Clinical Immunology* (8th Edition), Appleton & Lange, Norwalk, CT (1994) and Mishell and Shiigi (eds), *Selected Methods in Cellular Immunology*, W.H. Freeman and Co., New York (1980).

### Immunoassays

In general, ELISAs where appropriate are one of the immunoassays employed to assess a specimen. ELISA assays are well known to those skilled in the art. Both polyclonal and monoclonal antibodies can be used in the assays. Where appropriate other immunoassays, such as radioimmunoassays (RIA) can be used as are known to those in the art. Available immunoassays are extensively described in the patent and scientific literature. See, for example, United States patents 3,791,932; 3,839,153; 3,850,752; 3,850,578; 3,853,987; 3,867,517; 3,879,262; 3,901,654; 3,935,074; 3,984,533; 3,996,345; 4,034,074; 4,098,876; 4,879,219; 5,011,771 and 5,281,521 as well as Sambrook et al, *Molecular Cloning: A Laboratory Manual*, Cold Springs Harbor, New York, 1989

### Antibody Production

Antibodies can be either monoclonal, polyclonal or recombinant. Conveniently, the antibodies can be prepared against the immunogen or portion thereof for example a synthetic peptide based on the sequence, or prepared recombinantly by cloning techniques or the natural gene product and/or portions thereof can be isolated and used as the immunogen. Immunogens can be used to produce antibodies by standard antibody production technology well known to those skilled in the art as described generally in Harlow and Lane, *Antibodies: A Laboratory Manual*, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, 1988 and Borrebaeck, *Antibody Engineering - A Practical Guide*, W.H. Freeman

and Co., 1992. Antibody fragments can also be prepared from the antibodies and include Fab, F(ab')<sub>2</sub>, and Fv by methods known to those skilled in the art. For producing polyclonal antibodies a host, such as a rabbit or goat, is immunized with the immunogen or immunogen fragment, generally with an adjuvant and, if necessary, coupled to a carrier; antibodies to the immunogen are collected from the sera. Further, the polyclonal antibody can be absorbed such that it is monospecific. That is, the sera can be absorbed against related immunogens so that no cross-reactive antibodies remain in the sera rendering it monospecific.

For producing monoclonal antibodies the technique involves hyperimmunization of an appropriate donor with the immunogen, generally a mouse, and isolation of splenic antibody producing cells. These cells are fused to a cell having immortality, such as a myeloma cell, to provide a fused cell hybrid which has immortality and secretes the required antibody. The cells are then cultured, in bulk, and the monoclonal antibodies harvested from the culture media for use.

For producing recombinant antibody (see generally Huston et al, 1991; Johnson and Bird, 1991; Mernaugh and Mernaugh, 1995), messenger RNAs from antibody producing B-lymphocytes of animals, or hybridoma are reverse-transcribed to obtain complementary DNAs (cDNAs). Antibody cDNA, which can be full or partial length, is amplified and cloned into a phage or a plasmid. The cDNA can be a partial length of heavy and light chain cDNA, separated or connected by a linker, e.g., encoding a single chain antibody. The

antibody, or antibody fragment, is expressed using a suitable expression system to obtain recombinant antibody. Antibody cDNA can also be obtained by screening pertinent expression libraries.

The antibody can be bound to a solid support substrate or conjugated with a detectable moiety or be both bound and conjugated as is well known in the art. (For a general discussion of conjugation of fluorescent or enzymatic moieties see Johnstone & Thorpe, *Immunochemistry in Practice*, Blackwell Scientific Publications, Oxford, 1982.) The binding of antibodies to a solid support substrate is also well known in the art. (see for a general discussion Harlow & Lane *Antibodies: A Laboratory Manual*, Cold Spring Harbor Laboratory Publications, New York, 1988 and Borrebaeck, *Antibody Engineering - A Practical Guide*, W.H. Freeman and Co., 1992) The detectable moieties contemplated with the present invention can include, but are not limited to, fluorescent, metallic, enzymatic and radioactive markers such as biotin, gold, ferritin, alkaline phosphatase,  $\beta$ -galactosidase, peroxidase, urease, fluorescein, rhodamine, tritium,  $^{14}\text{C}$  and iodination.

#### Recombinant Protein Purification

Marshak et al, "Strategies for Protein Purification and Characterization. A laboratory course manual." CSHL Press, 1996.

#### Gene therapy:

The genes described in this patent can also be used as targets for gene therapy, since these genes can be of importance for the development of TCC. Therefore, targeted gene therapy against one or more of these genes, or against one or more of the corresponding polypeptides encoded by these genes, is applied to cure TCC and /or to retard the spread of TCC. BGene therapy as used herein refers to the transfer of genetic material (e.g. DNA or RNA) of interest into a host to treat or prevent a genetic or acquired disease or condition phenotype. The genetic material of interest encodes a product (e.g. a protein, polypeptide, peptide, functional RNA, antisense) whose production *in vivo* is desired. For example, the genetic material of interest can encode a hormone, receptor, enzyme, polypeptide or peptide of therapeutic value. Alternatively, the genetic material of interest encodes a suicide gene. For a review see, in general, the text "Gene Therapy" (Advances in Pharmacology 40, Academic Press, 1997).

Vectors can be introduced into cells or tissues by any one of a variety of known methods within the art. Such methods can be found generally described in Sambrook et al., *Molecular Cloning: A Laboratory Manual*, Cold Springs Harbor Laboratory, New York (1989, 1992), in Ausubel et al., *Current Protocols in Molecular Biology*, John Wiley and Sons, Baltimore, Maryland (1989), Chang et al., *Somatic Gene Therapy*, CRC Press, Ann Arbor, MI (1995), Vega et al., *Gene Targeting*, CRC Press, Ann Arbor, MI (1995), *Vectors: A Survey of Molecular Cloning Vectors and Their Uses*, Butterworths, Boston MA (1988) and Gilboa et al (1986) and include, for example, stable or transient

transfection, lipofection, electroporation and infection with recombinant viral vectors. In addition, see United States patent 4,866,042 for vectors involving the central nervous system and also United States patents 5,464,764 and 5,487,992 for positive-negative selection methods.

Introduction of nucleic acids by infection offers several advantages over the other listed methods. Higher efficiency can be obtained due to their infectious nature. Moreover, viruses are very specialized and typically infect and propagate in specific cell types. Thus, their natural specificity can be used to target the vectors to specific cell types *in vivo* or within a tissue or mixed culture of cells. Viral vectors can also be modified with specific receptors or ligands to alter target specificity through receptor mediated events.

A specific example of DNA viral vector for introducing and expressing recombinant sequences is the adenovirus derived vector Adenop53TK. This vector expresses a herpes virus thymidine kinase (TK) gene for either positive or negative selection and an expression cassette for desired recombinant sequences. This vector can be used to infect cells that have an adenovirus receptor which includes most cancers of epithelial origin as well as others. This vector as well as others that exhibit similar desired functions can be used to treat a mixed population of cells and can include, for example, an *in vitro* or *ex vivo* culture of cells, a tissue or a human subject.

Additional features can be added to the vector to ensure its safety and/or enhance its therapeutic efficacy. Such features include, for example, markers that can be used to negatively select against cells infected with the



recombinant virus. An example of such a negative selection marker is the TK gene described above that confers sensitivity to the antibiotic gancyclovir.

Negative selection is therefore a means by which infection can be controlled because it provides inducible suicide through the addition of antibiotic. Such protection ensures that if, for example, mutations arise that produce altered forms of the viral vector or recombinant sequence, cellular transformation can not occur.

Features that limit expression to particular cell types can also be included. Such features include, for example, promoter and regulatory elements that are specific for the desired cell type.

In addition, recombinant viral vectors are useful for *in vivo* expression of a desired nucleic acid because they offer advantages such as lateral infection and targeting specificity. Lateral infection is inherent in the life cycle of, for example, retrovirus and is the process by which a single infected cell produces many progeny virions that bud off and infect neighboring cells. The result is that a large area becomes rapidly infected, most of which was not initially infected by the original viral particles. This is in contrast to vertical-type of infection in which the infectious agent spreads only through daughter progeny. Viral vectors can also be produced that are unable to spread laterally. This characteristic can be useful if the desired purpose is to introduce a specified gene into only a localized number of targeted cells.

As described above, viruses are very specialized infectious agents that have evolved, in many cases, to elude host defense mechanisms. Typically,

viruses infect and propagate in specific cell types. The targeting specificity of viral vectors utilizes its natural specificity to specifically target predetermined cell types and thereby introduce a recombinant gene into the infected cell. The vector to be used in the methods of the invention depends on desired cell type to be targeted and is known to those skilled in the art. Thus, if bladder cancer is to be treated then a vector specific for such epithelial cells are used.

Retroviral vectors can be constructed to function either as infectious particles or to undergo only a single initial round of infection. In the former case, the genome of the virus is modified so that it maintains all the necessary genes, regulatory sequences and packaging signals to synthesize new viral proteins and RNA. Once these molecules are synthesized, the host cell packages the RNA into new viral particles which are capable of undergoing further rounds of infection. The vector's genome is also engineered to encode and express the desired recombinant gene. In the case of non-infectious viral vectors, the vector genome is usually mutated to destroy the viral packaging signal that is required to encapsulate the RNA into viral particles. Without such a signal, any particles that are formed do not contain a genome and therefore cannot proceed through subsequent rounds of infection. The specific type of vector depends upon the intended application. The actual vectors are also known and readily available within the art or can be constructed by one skilled in the art using well-known methodology.

The recombinant vector can be administered in several ways. If viral vectors are used, for example, the procedure can take advantage of their

target specificity and consequently, do not have to be administered locally at the diseased site. However, local administration can provide a quicker and more effective treatment, administration can also be performed by, for example, intravenous or subcutaneous injection into the subject. Following injection, the viral vectors circulate until they recognize host cells with the appropriate target specificity for infection.

An alternate mode of administration can be by direct inoculation into the bladder i.e., locally to the site of the disease or pathological condition or by inoculation into the vascular system supplying the site with nutrients. Local administration is advantageous because there is no dilution effect and, therefore, a smaller dose is required to achieve expression in a majority of the targeted cells. Additionally, local inoculation can alleviate the targeting requirement required with other forms of administration since a vector can be used that infects all cells in the inoculated area. If expression is desired in only a specific subset of cells within the inoculated area, then promoter and regulatory elements that are specific for the desired subset can be used to accomplish this goal. Such non-targeting vectors can be, for example, viral vectors, viral genome, plasmids, phagemids and the like. Transfection vehicles such as liposomes can also be used to introduce the non-viral vectors described above into recipient cells within the inoculated area. Such transfection vehicles are known by one skilled within the art.

#### Chemical compounds

The chemical compounds to be administered comprise inter alia small chemical molecules; antibodies of all types or fragments thereof including single chain antibodies; antisense oligonucleotides, antisense oligonucleotides, polynucleotides, DNA or RNA molecules; proteins, polypeptides and peptides including peptido-mimetics and dominant negative peptides; ribozymes; and expression vectors

#### Delivery of chemical compound

The compound of the present invention is administered and dosed in accordance with good medical practice, taking into account the clinical condition of the individual patient, the site and method of administration, scheduling of administration, patient age, sex, body weight and other factors known to medical practitioners. The pharmaceutically "effective amount" for purposes herein is thus determined by such considerations as are known in the art. The amount must be effective to achieve improvement including but not limited to improved survival rate or more rapid recovery, or improvement or elimination of symptoms and other indicators as are selected as appropriate measures by those skilled in the art.

In the method of the present invention, the compound of the present invention can be administered in various ways. It should be noted that it can be administered as the compound or as pharmaceutically acceptable salt and can be administered alone or as an active ingredient in combination with pharmaceutically acceptable carriers, diluents, adjuvants and vehicles. The compounds can be administered intravesically (directly into the bladder), orally,

subcutaneously or parenterally including intravenous, intraarterial, intramuscular, intraperitoneally, and intranasal administration as well as intrathecal and infusion techniques. Implants of the compounds are also useful. The patient being treated is a warm-blooded animal and, in particular, mammals including man. The pharmaceutically acceptable carriers, diluents, adjuvants and vehicles as well as implant carriers generally refer to inert, non-toxic solid or liquid fillers, diluents or encapsulating material not reacting with the active ingredients of the invention.

It is noted that humans are treated generally longer than the mice or other experimental animals exemplified herein which treatment has a length proportional to the length of the disease process and drug effectiveness. The doses can be single doses or multiple doses over a period of several days, but single doses are preferred.

The doses can be single doses or multiple doses over a period of several days. The treatment generally has a length proportional to the length of the disease process and drug effectiveness and the patient species being treated.

When administering the compound of the present invention parenterally, it is generally formulated in a unit dosage injectable form (solution, suspension, emulsion). The pharmaceutical formulations suitable for injection include sterile aqueous solutions or dispersions and sterile powders for reconstitution into sterile injectable solutions or dispersions. The carrier can be a solvent or dispersing medium containing, for example, water, ethanol, polyol (for

example, glycerol, propylene glycol, liquid polyethylene glycol, and the like), suitable mixtures thereof, and vegetable oils.

Proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. Nonaqueous vehicles such as cottonseed oil, sesame oil, olive oil, soybean oil, corn oil, sunflower oil, or peanut oil and esters, such as isopropyl myristate, can also be used as solvent systems for compound compositions. Additionally, various additives which enhance the stability, sterility, and isotonicity of the compositions, including antimicrobial preservatives, antioxidants, chelating agents, and buffers, can be added. Prevention of the action of microorganisms can be ensured by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, and the like. In many cases, it is desirable to include isotonic agents, for example, sugars, sodium chloride, and the like. Prolonged absorption of the injectable pharmaceutical form can be brought about by the use of agents delaying absorption, for example, aluminum monostearate and gelatin. According to the present invention, however, any vehicle, diluent, or additive used have to be compatible with the compounds.

Sterile injectable solutions can be prepared by incorporating the compounds utilized in practicing the present invention in the required amount of the appropriate solvent with various of the other ingredients, as desired. A pharmacological formulation of the present invention can be administered to the patient in an injectable formulation containing any compatible carrier, such as

various vehicle, adjuvants, additives, and diluents; or the compounds utilized in the present invention can be administered parenterally to the patient in the form of slow-release subcutaneous implants or targeted delivery systems such as monoclonal antibodies, vectored delivery, iontophoretic, polymer matrices, liposomes, and microspheres. Examples of delivery systems useful in the present invention include: 5,225,182; 5,169,383; 5,167,616; 4,959,217; 4,925,678; 4,487,603; 4,486,194; 4,447,233; 4,447,224; 4,439,196; and 4,475,196. Many other such implants, delivery systems, and modules are well known to those skilled in the art.

A pharmacological formulation of the compound utilized in the present invention can be administered orally to the patient. Conventional methods such as administering the compounds in tablets, suspensions, solutions, emulsions, capsules, powders, syrups and the like are usable. Known techniques which deliver it orally or intravenously or directly to the bladder (intravesically) and retain the biological activity are preferred. In one embodiment, the compound of the present invention can be administered initially by intravenous injection to bring blood levels to a suitable level. The patient's levels are then maintained by an oral dosage form, although other forms of administration, dependent upon the patient's condition and as indicated above, can be used. The quantity to be administered vary for the patient being treated and vary from about 100 ng/kg of body weight to 100 mg/kg of body weight per day and preferably are from 10  $\mu$ g/kg to 10 mg/kg per day.

## EXAMPLE 2

### POLYNUCLEOTIDES AND DIAGNOSTIC APPLICATIONS

Utilizing the methods set forth above, the polynucleotides set forth in Tables I and 2 were identified and cloned as being differentially expressed in bladder cancer. 41 hybridizations were compared.

The polynucleotides described in Table I are identified by clone number and accession number. This list includes sequences of known genes whose function in bladder cancer was heretofore unknown and which were now found to upregulated in bladder cancer. Corresponding nucleic acid sequences are provided in Table 3.

The polynucleotides described in Table 2 are identified by clone number. This list includes sequences of novel genes which have no identity to known proteins or genes in the gene databases. Corresponding nucleic acid sequences are provided in Table 4.

In both Tables I and 2, the differential expression pattern of the different hybridization probes is provided. In both Table I and 2, the genes listed were found to be upregulated in at least 60% of TCC samples and unchanged in at least 75% of the normal samples.

Tables I and 2 show the genes as described in biological NCBI databases, with the Genbank number of each gene (where applicable) as presented in the NCBI database. The location of the clone in the TCC microarray of the present invention is set forth in the tables, with their clone ID in the TCC chip.



The expression differentials described in Tables 1 and 2 were calculated as follows: Since a common control probe was used for all hybridizations and the hybridizations were carried out in three separate sets, the expression differentials in each respective set were calculated as compared to one of the normal bladder samples, as a reference probe.

Thus, hybridization set 1 which includes hybridizations TC2-TC11, all the results are shown as compared to the TC7 (normal) hybridization result. In hybridization set 2 which includes hybridizations TC16-TC25, all the results were calculated in comparison to the TC22 (normal) hybridization result. In set 3, which includes hybridizations TC28-TC41, all the results were calculated compared to the reference normal probe from TC47.

### **EXAMPLE 3: KEY GENES**

In the present invention, the results of the 41 hybridizations were analyzed on the TCC microarray, in order to provide a statistically meaningful set of genes (which each include one of the polynucleotides identified) that can identify TCC samples and be used as a TCC marker set. As a result, a sub-set of twenty-two (22) potential molecular markers for non-invasive TCC was identified and validated using supervised statistical analysis methods. The 22 genes identified as potential markers (listed in Table 5) code for secreted factors, cytoskeletal and membranal proteins, all potentially suitable for the development of non-invasive diagnostic tests. This marker set of genes is described below, in

Example 4, Section 5, entitled "Expression patterns, scores and significance values for 22 short-listed genes", and related Tables C1 and C2.

Thirteen (13) of these 22 polynucleotides are described in Example 2 ( see Tables 1-4), and nine (9) are newly described in this Example (see Tables 5-6). In Table 5, the polynucleotides already described in Tables 1 and 2 are designated with an "X".

The 22 gene marker set was identified following reanalysis of the 41 hybridizations. All the experiments were constructed so that such an analysis can be performed. The hybridization scheme (described in Section 1 hereunder) was based on both individual sample hybridizations and a common control approach. All the hybridizations passed quality control examination and pre-processing steps (described in Sections 2 and 3 hereunder) which are critical to establish input material suitable for any statistical analysis. Following these pre-processing steps, the hybridization data was scored according to its "similarity" to the desired discrimination - non-invasive TCC *versus* normal urothelium (see Example 5).

Two independent (though related) standard scoring methods were used and individual genes were selected that discriminate between non-invasive TCC and normal urothelium (see Example 5, Section 4).

Full bioinformatic annotation analysis of the 22 listed genes (see Example 5, Section 6) and detailed description of their potential biological relevance to cancer in general and to TCC in particular is presented herein (see Example 5, Sections 6 and 7).

Based on the sequence annotation, 17 of the selected 22 markers were found to be known, characterized genes and 5 code for genes with an unknown protein product. At least four of the known genes and 1 of the genes with yet unknown protein products code for membranal or secreted proteins, based on the Applicants' proprietary "secreted" probe (described in co-assigned USSN 09/534, corresponding to PCT patent publication number WO 00/56935 which is incorporated herein by reference in its entirety) and on domain analysis. (See Example 5, Sections 4 and 6). Being secreted, some of these proteins can be identified in body fluids (in particular urine), thus alleviating the need for invasive tests. All other non-secreted proteins can also be detected in urine, which always contains shedded urothelial cells.

For a diagnostic assay, urine samples of TCC patients and of non-TCC patients should be analyzed. Urine can be collected, preserved in  $-70^{\circ}\text{C}$  and used either for protein assays (Western analysis) with the relevant antibody and/or for ELISA tests with the same relevant antibody. Similarly, blood samples from the same donors can be collected, and the separated serum samples can be used for detection of the candidate proteins in the serum using similar protein analysis approach. After establishing the particular assay for a single protein, assays for a combination of 2 or more different proteins can be set to increase the validity of the obtained results for each sample and to obtain robustness.

According to biomedical literature, the 17 known genes were classified into three functional groups: tumorigenesis, keratinocyte differentiation, and cell motility and proliferation. Thus, these markers can also fulfill a functional

role in TCC. Being functionally relevant these genes can be used as possible targets for genes therapy for TCC. This can be achieved by antagonizing their affects in the tumor using antisense delivery approach (for all such proteins), blocking their enzymatic activity (for enzymes), or specific drug delivery, as relevant. Since different keratins were detected as being differentially expressed in TCC, specific typing of the different keratins in urine of TCC patients, using a single multi-gene assay, can facilitate and improve robust TCC diagnostics.

The specificity of markers for TCC over other cancers is an important consideration. In particular, the expression level of the selected gene set is analyzed in other urogenital cancers, such as renal carcinoma and prostate cancer. Importantly, samples obtained from clinically relevant controls, such as inflammation or benign prostate hyperplasia (BPH) must be included. Retrospective studies of patients is also be carried out, as well as comparison of samples obtained during follow-up procedures (to monitor tumor progression in TCC patients).

All the genes described in the present invention are tested for their level of expression of exfoliated cells in urine, according to the following protocol. Urine samples (e.g. 100ml of urine) are collected from 3 different populations: healthy donors, TCC patients and a relevant control group (e.g., prostate cancer, bladder inflammation). The exfoliated cells are separated from urine (it is possible to keep the separated cells in  $-70^{\circ}\text{C}$  pending further work) and used for preparation of RNA. Such an approach enables tracking cancer-related changes at the level of gene expression. Following RNA extraction, RT-PCR is performed

for selected genes. Primers specific for each of these genes are constructed and used for the amplification of the cDNA products, being constructed so that each of the tested genes are amplified to a fragment of a different size. RT-PCR reaction is carried out in semi-quantitative approach. Fractionation for the resultant products on gels indicates the relative abundance of each of the tested genes in the tested RNA sample. Alternatively, TaqMan (Applied Biosystems) enables a fully quantitative time-course demonstration of the level of expression of these genes. Results for each of the tested genes are defined and documented and used for statistical analysis. Finally, a value is calculated for the expression of the predictor gene set in TCC and in non-TCC samples.

Comparison of the expression level results for a given unknown sample to this known calculated value predicts if the tested sample contains TCC (under certain confidence level,  $p$  value). All information from the tested samples is gathered during the establishment of the described diagnostic protocol and the statistical analysis is expanded so that all samples participating in the study are included.

According to the present invention, gene sequences are included which are uniformly expressed in normal and TCC tissues (see Example 5, Section 8). These genes can be used as an internal control in each multiplex RT-PCR. To this end primers for amplification of such genes are constructed and applied within the RT-PCR reaction of the marker gene set.

In further analysis, the results obtained from a single donor are compared between different tissues obtained from the same donor, e.g., matched urine exfoliated cells and tumor tissue (for RT-PCR approach) or urine

and blood for the protein analysis approach. This enables a deeper understanding of the molecular changes associated with TCC and their general presentation in different organs.

The genes provided in the present patent application can also be used for printing a small diagnostic TCC mini-microarray. This chip includes also clones with a uniform high expression in both normal urothelium and TCC (see Example 5, Section 8). Such TCC mini-microarray can be used for both disease detection and validation and for molecular staging and grading of the TCC tumors. Samples for hybridization on such chip include material derived from TCC tumors and from normal urothelium from different donors.

In addition, urine exfoliated cells from the same donors can be used for RNA extraction and RNA amplification. The RNA can be used for generating cDNA probes for the TCC mini cDNA microarray. This enables characterization of gene expression patterns of all the printed genes and comparison between the expression pattern obtained using tissue-type material to that obtained by cells shedded in urine. Since shedded cells are also collected from non-TCC donors such as patients with BPH and inflammation, these also comprise part of the hybridization probes.

The present invention further presents the use of a small subset of genes (2 or more genes) together for providing an accurate diagnostic test for TCC. With one exception (the cytokeratin 8 and 18 assay), all commercially existing molecular diagnostics for TCC are based on tests for single proteins. These can be insufficient to account for the inherent complexity of cancer, as

well as for the variability of both healthy and affected populations. To this end, the present invention describes the use of a combination of several genes and/or proteins either as a marker set for detection of these proteins in urine or in other body fluids, and/or by using the cells or cell debris present in the urine of TCC patients for multiple-gene RT-PCR diagnostic testing.

In-situ hybridization analysis using the same gene set can be performed as an auxiliary qualitative validation step, using paraffin blocks from normal urothelium and TCC tumors.

The genes of the present invention also characterize different stages of TCC. Correct "staging" of TCC is fundamental for the management of this disease. Upon detection of a new TCC patient, the developmental stage of the tumors determines relevant treatment. For example, if a non-invasive tumor is identified, "TURP" is the surgical approach recommended. If, however, the tumor is defined as invasive TCC, cystectomy is usually the treatment of choice. Identification of those non-invasive TCC patients that might progress is of great clinical value.

Keratin 13 is identified herein as a marker that can differentiate Ta from T1 and invasive tumors (see Section 10). The analysis described in the present invention indicates a clear discrimination between Ta and T1 tumors, where this gene is upregulated in Ta tumors and downregulated in T1 tumors when compared to normal urothelium. This gene includes part of the diagnostic tests described.

According to the present invention, 22 polynucleotides included in Tables 1 – 6, 22 genes were identified; these genes serve as potential markers for TCC, especially for non-invasive TCC. These genes, and all the genes included in Tables 1 – 6, can be used for diagnosis of TCC.

Full-length genes or gene fragments are suggested as markers for non-invasive assays. PCR products, antisense products, protein products and antibodies raised against these genes can be applied both for diagnostics for TCC and for targeted gene therapy. The tests for the levels of these genes and/or proteins can be performed in body fluids, in the original tumor or in other relevant body organs, and in cells found in the urine of patients.

## **EXAMPLE 4 :HYBRIDIZATIONS AND STATISTICAL ANALYSIS**

### **Section 1. Hybridization scheme**

The hybridization scheme according to the present invention is based on three principles

1. Individual hybridization of each sample (normal or TCC) whenever possible: This provides a comprehensive overview of the entire sample set, with minimal a-priori assumptions, and with maximal measurement of the variability between the samples. Such individual hybridization procedure is crucial for successful analysis of the results. In a small number of cases, due to insufficient amounts of normal urothelium material, pools of several normal samples were used as a single probe (See Table A, 3<sup>rd</sup> set).



## 2. Utilization of an identical common normalizing probe

("Common Control" or "CC") in each set of hybridizations: By maintaining one of the probes as a constant, common probe, hybridization results can be compared across experiments. The common normalizing probe used in the present invention was prepared from a pool of RNA from different TCC and normal samples. This material should be similar in composition to the one used for construction of the TCC microarray. Thus, it has a high probability to hybridize and detect a maximal number of elements on the TCC array, and to provide an appropriate normalization of signals between hybridizations.

## 3. Secreted and membranal proteins have an obvious

advantage as molecular markers. The "secreted" probe allows sequence-independent identification of genes potentially coding for secreted and membranal proteins. If such genes are highly expressed in tumors it is plausible to try to find their protein products highly expressed in urine, too.

Hybridizations of TCC and of normal urothelium samples were performed in 3 sets which were separated in time as well as in the methods of RNA preparation (polyA and total), as shown in Table A. Although these differences increase the variability of the results, they also suggest that the identified phenomena are robust to experimental intricacies. Comparison of gene expression results between the sets increases the validity of the results obtained. Differences in RNA preparation can also affect the common normalizing probe. For example, in the first two sets an identical total RNA pool was used (Table A common normalizing probe1), while in the 3<sup>rd</sup> set polyA RNA was extracted from

the same pool of total RNA and used as a common control (Table A, common normalizing probe2).

Table A: Detailed hybridization scheme

Set number	Probe type	Probe 1 (Cy3)	Probe 2(Cy5): "Experiment" probe			
			Type (# samples)	Code	Stage	Grade
1	Total RNA	Common normalising probe1 (total RNA)	TCC (5)	TC2	T1	
				TC3	T1	G2/G3
				TC4	T1	G2/G3
				TC5	T1	
				TC6	T1	
			Normal (5)	TC7	normal	
				TC8	normal	
				TC9	normal	
				TC10	normal	
				TC11	normal	
2	Total RNA	Common normalising probe1 (total RNA)	TCC (6)	TC16	Ta	G2
				TC17	Ta	G2
				TC18	Ta	High
				TC19	T1	Low
				TC20	T1	G3
				TC25	T1	G1
			Normal (4)	TC22	normal	
				TC22	Normal	
				TC23	Normal	
				TC24	Normal	
3	Poly A RNA	Common normalising probe2 (poly A)	TCC (14)	TC28	T1+TIS	G3
				TC29	T1	High
				TC30	T1	G3
				TC31	Ta	G1/2
				TC32	Ta/T1	G2
				TC33	Ta	G2
				TC34	invasive	G3
				TC39	Ta	low
				TC40	T1	G1/2
				TC41	Ta	G2
				TC42	Ta	G2
				TC43	T1	G2
				TC44	Ta	G2
				TC45	invasive	G3
			Normal (19)	TC35	Normal	
				TC36	Normal	
				TC37	Normal pool	
				TC38	Normal pool	
				TC46	Normal	
				TC47	normal pool	
				TC48	normal pool	
Set number	Probe type	TCC invasive cell line	Code	Probe 1(Cy3)	Probe 2(Cy5)	
4	Secreted	SW780	TC49	Free polysomal RNA	Membrane bound polysomal RNA	
		T24	TC50			

In order to identify secreted and membranal proteins, two "secreted" probes were prepared from human invasive TCC cell lines, T24 and SW780. Briefly, membrane-bound polysomes were separated from free polysomes using sucrose step gradient. RNA coding for potentially secreted proteins was isolated from the microsomal-membranal fraction and RNA coding for intracellular proteins from the free polysomal pellet. Each RNA ("Secreted" and "Intracellular") was labelled with a different dye and hybridized to the TCC array (Table A, set 4). Significant differential expression in one of the probes is an indication of potential cellular compartments (intracellular or secreted/membranal). As a convention, a negative differential represents secreted proteins.

## **Section 2. Quality control (QC), preliminary evaluation**

In order to ensure the quality of the results shows in the present invention and to minimize experimental artefacts, all hybridization results underwent several standard QC steps. Since the hybridizations were performed in three separate sets, QC procedures were done *within* sets, consistent with inventors' past experience.

1. Reproducibility of the common control probe. Relative expression levels are compared across hybridizations due to the use of a common normalizing probe. However, this can be faithfully performed only if the common control probe behaves consistently across each set of hybridization. This consistency is first measured by the pair-wise correlations between the

common control signal vectors. The pair-wise correlation coefficient between common control probes in each set are almost invariably very high (>0.97, Table B1). These results indicate the suitability of common control-based normalization for this data set.

Table B1: Common control correlations (by hybridization set) for 41 TCC hybridizations

Set #1	TC10	TC11	TC2	TC3	TC4	TC5	TC6	TC7	TC8	TC9
TC10	1.00	.96	.97	.97	.97	.98	.98	.97	.87	.98
TC11	.96	1.00	.97	.98	.97	.97	.97	.97	.88	.98
TC2	.97	.97	1.00	.98	.98	.98	.98	.98	.88	.98
TC3	.97	.98	.98	1.00	.99	.98	.99	.98	.89	.98
TC4	.97	.97	.98	.99	1.00	.99	.98	.97	.88	.98
TC5	.98	.97	.98	.98	.99	1.00	.98	.97	.88	.98
TC6	.98	.97	.98	.99	.98	.98	1.00	.98	.89	.99
TC7	.97	.97	.98	.98	.97	.97	.98	1.00	.89	.98
TC8	.87	.88	.88	.89	.88	.88	.89	.89	1.00	.89
TC9	.98	.98	.98	.98	.98	.98	.99	.98	.89	1.00

Set #2	TC16	TC17	TC18	TC19	TC20	TC21	TC22	TC23	TC24	TC25
TC16	1.00	.98	.97	.98	.98	.97	.98	.97	.97	.97
TC17	.98	1.00	.98	.99	.98	.98	.98	.98	.97	.98
TC18	.97	.98	1.00	.98	.97	.97	.97	.97	.96	.97
TC19	.98	.99	.98	1.00	.98	.98	.98	.97	.97	.97
TC20	.98	.98	.97	.98	1.00	.98	.98	.97	.97	.97
TC21	.97	.98	.97	.98	.98	1.00	.98	.97	.97	.97
TC22	.98	.98	.97	.98	.98	.98	1.00	.98	.97	.98
TC23	.97	.98	.97	.97	.97	.97	.98	1.00	.97	.97
TC24	.97	.97	.96	.97	.97	.97	.97	.97	1.00	.96
TC25	.97	.98	.97	.97	.97	.97	.98	.97	.96	1.00

Set #3	TC 28	TC 29	TC 30	TC 31	TC 32	TC 33	TC 34	TC 35	TC 36	TC 37	TC 38	TC 39	TC 40	TC 41	TC 42	TC 43	TC 44	TC 45	TC 46	TC 47	TC 48
TC28	1.00	.99	.97	.98	.98	.98	.98	.98	.99	.99	.99	.98	.98	.97	.97	.98	.97	.97	.97	.98	.96
TC29	.99	1.00	.97	.97	.98	.98	.98	.97	.98	.98	.98	.97	.98	.97	.97	.98	.97	.96	.97	.97	.96
TC30	.97	.97	1.00	.98	.98	.98	.98	.98	.99	.98	.98	.98	.98	.97	.97	.98	.97	.97	.96	.97	.96
TC31	.98	.97	.98	1.00	.99	.98	.98	.98	.99	.99	.99	.98	.98	.98	.98	.98	.97	.97	.97	.97	.97
TC32	.98	.98	.98	.99	1.00	.99	.99	.98	.99	.99	.99	.98	.98	.98	.97	.98	.97	.96	.96	.97	.95
TC33	.98	.98	.98	.98	.99	1.00	.99	.98	.99	.99	.99	.98	.98	.98	.97	.98	.97	.96	.96	.97	.95
TC34	.98	.98	.98	.98	.99	.99	1.00	.98	.99	.99	.99	.98	.98	.97	.97	.98	.97	.96	.96	.97	.95
TC35	.98	.97	.98	.98	.98	.98	.98	1.00	.98	.98	.98	.97	.97	.97	.96	.98	.96	.96	.95	.96	.95
TC36	.99	.98	.99	.99	.99	.99	.99	.98	1.00	.99	.99	.99	.98	.98	.98	.99	.97	.97	.97	.98	.97
TC37	.99	.98	.98	.99	.99	.99	.99	.98	.99	1.00	.99	.99	.99	.98	.98	.98	.99	.97	.97	.98	.97
TC38	.99	.98	.98	.99	.99	.99	.99	.98	.99	.99	1.00	.98	.99	.98	.98	.98	.98	.98	.97	.98	.97
TC39	.98	.97	.98	.98	.98	.98	.97	.98	.99	.98	.98	1.00	.99	.98	.98	.97	.97	.97	.97	.97	.97
TC40	.98	.98	.98	.98	.98	.98	.97	.99	.99	.99	.99	.99	1.00	.98	.98	.99	.98	.98	.97	.98	.97
TC41	.97	.97	.97	.98	.98	.98	.97	.97	.98	.98	.98	.98	.98	1.00	.98	.98	.97	.97	.97	.97	.97
TC42	.97	.97	.97	.98	.97	.97	.96	.97	.98	.98	.98	.98	.98	.98	1.00	.98	.97	.98	.97	.97	.97
TC43	.98	.98	.98	.98	.99	.98	.98	.98	.99	.99	.99	.98	.98	.98	.98	1.00	.97	.97	.97	.97	.97
TC44	.97	.97	.97	.97	.98	.97	.97	.96	.97	.97	.97	.98	.98	.97	.97	.97	1.00	.98	.97	.98	.98
TC45	.97	.96	.97	.97	.97	.96	.96	.96	.97	.97	.97	.98	.98	.97	.97	.97	.97	1.00	.99	.99	.99
TC46	.97	.97	.96	.97	.97	.96	.96	.95	.96	.97	.97	.97	.97	.97	.97	.97	.97	.98	1.00	.99	.99
TC47	.98	.97	.97	.97	.98	.97	.97	.96	.98	.98	.98	.98	.98	.97	.97	.97	.98	.98	.99	1.00	.99
TC48	.96	.96	.96	.97	.97	.95	.95	.95	.96	.97	.97	.97	.97	.97	.97	.97	.98	.99	.99	.99	1.00

2. Signal quality. A second measure of hybridization quality is the number of elements which yielded a significant signal and a reliable signal to background (S2B) ratio with each probe. Since a custom cDNA array was used, both experiment and control probes are expected to yield a similar number of significant signals (A set of  $n$  hybridizations of an  $m$ -gene array is typically treated as a matrix  $A$  of size  $m \times n$ . Thus the expression level of each gene in all  $n$  hybridizations is a vector of size  $m$  ("gene vector")). A single hybridization experiment is represented by a vector of  $m$  expression measurements ("hybridization vector"). In differential profiling the vector can represent a single probe (in which case it is a vector of signals) or both (a vector of differentials)). Thus, when comparing the hybridization quality of the common control probes, pair-wise correlation was calculated between the common control signal vector in one hybridization to that of another. Missing values were deleted on a case-wise basis. Traditional threshold (200 units) for signals, for both common control and tested sample probes, and S2B (value of 2.5 for at least 40% coverage of element) were used (Table B2).

The first and third sets of hybridizations yielded signals of high quality in both common control and experiment probes. The quality of the second set was significantly lower (Table B2).

Table B2: Signal quality (by hybridization set)

Set #1

Code	Significant P1	Significant P2
TC10A	6679	6450
TC11A	5280	4546
TC2A	5834	5097
TC3A	6603	5691
TC4A	6319	4706
TC5A	6528	5589
TC6A	6773	6099
TC7A	6456	6016
TC8A	5762	5376
TC9A	6715	5929

TC46 A	6261	5030
TC47 A	6057	5206
TC48 A	5051	4109

Set #2

Code	Significant P1	Significant P2
TC16A	1762	1964
TC17A	1758	2063
TC18A	1543	1822
TC19A	1766	1987
TC20A	1578	1708
TC21A	1604	1540
TC22A	1700	1812
TC23A	1656	1832
TC24A	1417	1408
TC25A	1255	1555

Set #3

Code	Significant P1	Significant P2
TC28 A	8084	7690
TC29 A	7519	6887
TC30 A	7449	7404
TC31 A	7294	6697
TC32 A	7284	6529
TC33 A	7724	6919
TC34 A	7236	7282
TC35 A	7758	7258
TC36 A	7410	7089
TC37 A	7291	7583
TC38 A	7353	6760
TC39 A	6370	6321
TC40 A	6754	6722
TC41 A	6183	5502
TC42 A	5758	5501
TC43 A	7137	7013
TC44 A	5576	5335
TC45 A	4920	4917


3. Relationships between hybridizations. Hierarchical clustering of the hybridizations in each set provides an additional, albeit preliminary, estimate of quality. Either the Pearson correlation coefficient or a standard Euclidean distance was used as the distance measure between differential hybridization vectors. Hybridizations were clustered according to these distances by average linkage hierarchical clustering. Missing values were deleted on a case-wise basis. Clusters of hybridizations can be identified and evaluated in light of existing knowledge.

Many of the unexpected phenomena can indicate the limitation of previous understanding, and serve as a starting point for class definition. However, "outlying" hybridizations can also indicate quality problems. Overall, in each set (Table B3) most of the separation between hybridizations is consistent with the expected TCC and normal urothelium separation. Even in hybridizations of lower quality, such as those of the second set, a clear separation between TCC and normal samples is observed.


One of the TCC samples in the first set (TC6) is such an "outlier" (Table B3), as well as one of the normal samples in the second set, and another normal sample (TC35) in the third. (The "outliers" do not appear to be misclassifications). For example, TC35 (a normal sample which is an "outlier" in the third set) does not behave like a TCC sample. Rather those genes that are up-regulated in TCC samples are down-regulated in TC35).

**Table B3: Relationships between hybridizations: Hierarchical clustering of hybridizations (by sets)**

**SET #1**



**SET #2**




Pearson correlation


Euclidean



# Set#3





## Pearson correlation



## Euclidean

Table B4 Hierarchical clustering of hybridizations (All Sets)



None of the "outliers" was eliminated from subsequent analysis steps. Rather, they were included to facilitate the selection of a more robust marker set (Table B3). Here, more complex relations are observed between global expression profiles. First, the two invasive hybridizations (TC34 and TC45), are distinct from other TCC samples (Tables B3 and B4). Second, the relationship between global Ta and T1 profiles is not straightforward. Most of the Ta samples form a unique cluster in the 3rd set, while the T1 samples are more dispersed.

### **Section 3. Pre-processing of the hybridization data.**

All hybridization data, even of good global quality, was filtered and processed prior to additional large scale analysis. This included global balancing of signals, identification and treatment of problematic signals, normalization of the hybridization data and filtering.

1. Signal Balancing. Differences in labeling and hybridization can bias the signals obtained with a Cy3 probe relative to the Cy5 probes. For each hybridization, linear balancing is used to overcome this bias. The balancing coefficient is calculated as  $(\text{sum P1})/(\text{Sum P2})$ .

2. Problematic signals. Two types of problematic signals are identified: very low signals and exceptionally variable signals. The first are signals below a pre-set threshold. The second are common control signals which significantly ( $>2$  SDs) deviate from the average common control signal for a given

element. All problematic common control signals were replaced with the average signals for the common control in the given element.

3. Normalization. In order to obtain meaningful differential expression values (TCC vs. normal) and to reduce differences between sets (inter-block variance), a second step of normalization is performed. In this step, each of the balanced differential expression levels (relative to the common control) is normalized by the average differential expression of the given element in the normal samples of the same set. The resulting normalized differential values give a measure of the difference between the expression of the element in a given sample (normal or TCC) and the average expression levels in normal tissues. Note that due to the use of averages in replacement of problematic signals, the variability in the normal samples is reduced by this procedure.

4. Filtering. In order to reduce the data set and limit it to higher-quality elements there was restricted from further analysis any overall weak elements (no signal above 200) and any non-differential elements (for which no normalized differential values exceeds  $|1.7|$ ). The remaining number of elements following these filters is 6693. Low-quality elements (where more than 20% of signals are problematic) were filtered only in later stages.

#### **Section 4. Class Prediction: Normal urothelium vs. non-invasive TCC and selection of marker set of genes**

To discriminate between normal urothelium and non-invasive TCC, each of the gene with hybridization value is scored according to its "similarity" to the desired discrimination- N vs Non invasive TCC. Two independent (though related) standard scoring methods from the three described below were used.

### **Statistical Methods for Class prediction**

#### **Scoring methods**

a. Student's unpaired t-test: The t-test is a statistic for measuring the significance of a difference of the means between two distributions ( $m_1$ , and  $m_2$ ) considering the variance ( $s_1^2$  and  $s_2^2$ ) within each group. The two populations are expected to be drawn from a normal distribution. In the case, these are the mean expression levels of a gene in normal urothelium and in TCC tumors, which are supposed to have a log-normal distribution (thus, log values are used). Statistical significance estimates (p-values) available for the t statistic. Since a large number of measurements is available for a small number of samples, a much more stringent threshold of significance is used ( $p < 10^{-6}$ ), which, according to the Benferroni adjustment corresponds to  $p < 0.001$ .

a. estimation of prediction error: This method scores genes according to probability of error or misclassification. As part of this procedure a discrimination threshold is determined. The threshold  $T(g_j)$  is taken such that the two types of misclassification error become equal, as:

$$(D.1) T(g_j) = [m_1(g_j) \cdot s_2(g_j) + m_2(g_j) \cdot s_1(g_j)] / [s_1(g_j) + s_2(g_j)]$$

and the significance of the misclassification error is given by

$$(D.4) P = 1 - F[(T(g_i) - m2(g_i))/s2(g_i)]$$

where F is a distribution function  $N(0,1)$ .

**b. Receiver Operating Characteristics (ROC) curves.** ROC

curves are used to evaluate the power of a classification method for different asymmetric weights of false negative vs. false positive errors (or sensitivity vs. specificity). In diagnostic applications false negative errors can be detrimental while false positives can be tolerated. A ROC curve plots the tradeoff between the two types of errors as the classification threshold varies. For each potential threshold, the rate of true positives is plotted against the rate of false positives. Accuracy (A) is indexed by the area under the curve. A straight line (i.e. 50:50 chance of correct diagnosis, no better than chance), has  $A=0.5$ . Perfect accuracy ( $A=1$ ) means that for a given threshold all predictions are correct.

The first score used is the "student's unpaired t-test", as above-described, i.e., one-way ANOVA with two classes, which reflects the difference between the classes relative to the variance within classes. The distribution of this statistic is resolved and significance levels of each score (its p-value) can be derived. The second method used scored genes according to an "estimation of prediction error", as described above, which again provides significance estimates (p-values) in a straightforward way.

Both scoring methods yielded similar numbers of elements with statistically significant scores: 77 elements according to the t-test scores ( $p < 10^{-6}$ ), and 63 elements with low misclassification errors.

This list was further narrowed according to several additional considerations:

1. Exclusivity of up-regulated genes. Non-invasive tests, such as a urine test, require the identification of tumor cells or proteins on a considerable background of normal tissue. Since the inventors assume that only significantly up-regulated TCC genes have a chance to be detected on such background, while genes down-regulated in TCC are not be faithfully detected in non-invasive tests, they specifically selected such genes according to their normalized differentials. Furthermore, genes having a particularly low expression in normal tissues were prioritized, to minimize detection problems in further assays.

2. Consistent scores. Elements with high scores in both methods were prioritized in the final list. The error-based method was given preference over the t-test scores due to the prediction threshold it provides.

3. Redundancy. Approximately half of the clones on the array were derived by a subtraction procedure (SSH) enriching for TCC up-regulated clones. Inevitably, this significantly increases array redundancy, especially for up-regulated genes. In order to address this problem, a large portion of the significantly scored clones and up-regulated genes has been sequenced (~900

clones). Only a single representative of each redundancy group was retained in the list.

4. Element quality. A stricter threshold of element quality was added, and only elements with less than 8 problematic signals were included (in most genes a much smaller number of problematic signals was encountered).

5. Gene identity. The functional role fulfilled by different genes as well as previous knowledge can change their priority. For example, one low-scoring gene (FABP) was selected due to its involvement in psoriasis and squamous cell carcinoma of the bladder.



## **Section 5. Expression patterns, scores and significance values for the 22 short-listed genes of the invention**

The final subset of informative genes comprises the top 22 up-regulated genes after application of consistency, redundancy, and quality filters. These genes obtained high scores as discriminators by both scoring methods.

The differential expression patterns, statistical scores and significance values for the 22 selected genes are shown in Table C1. The expression levels are shown in the Table in the following order:

Normal urothelium (16 first hybridizations);

T1 samples (13 hybridizations);

Ta samples (10 hybridizations).

The levels of differential expression and the signal values of the 2 "Secreted" probes are also shown (Table C1, four columns headed "Secreted..."). Strong negative differentials indicate a gene potentially encoding a secreted or membranal protein.


The statistical scores are given in the following order:

1. Estimation of mis-classification error is given under column "Error1\_2", 2. P value - Fisher criteria (similar to T-test) is shown as P-values, (column "PvalueFisher"), and 3. ROC value in the column headed with the same name.

Table C2 includes the raw measured signals for each gene in 39 hybridizations. P1 are the common control signals. P2 signals represent the measured tissue samples, and are thus more interesting. The genes are sorted by statistical significance with the top gene having the highest score. This is also the order in which they have been incorporated into the predictor (Table D1).

**Table D1: Unsupervised analysis of tumor samples**

**Hierarchical clustering of tumor samples (3<sup>rd</sup> set)**



## **Section 6. Sequence annotation and bioinformatic analysis of the genes with unknown protein product**

As shown in Table A, set 4, based on sequence annotation, 17 of the selected 22 markers are known, characterized genes; 3 additional genes code for hypothetical proteins. (One of these hypothetical proteins was identified through an EST contig of the original clone). The remaining 2 clones code for novel sequences. For one of them an EST contig was assembled, but homologous genes were not found. Only limited information is available for the 5 novel or uncharacterized genes. According to the "Secreted" probe, as described herein, one of them, the CGI-81 hypothetical protein, is a potentially secreted or membranal protein. Domain analysis also indicated the presence of a transmembranal domain in this protein. The other four genes cannot be classified with confidence, although the unknown gene in clone 70E8, can be marginally classified as "potentially secreted". No additional significant domains were identified.

## **Section 7. Bioinformatic analysis of known genes**

According to the biomedical literature, the 17 known genes were classified into three functional groups: tumorigenesis, keratinocyte differentiation, and cell motility and proliferation. Thus, these markers fulfil a functional role in TCC. It was noted that in a previous analysis, performed with sample pools on a general-purpose human microarray, similar functional groups (and in some cases

the same genes) were identified, further validating the results of this study (see co-assigned patent application USSN 09/534,661 corresponding to PCT patent publication number WO 00/56935 )

Only a few of these 17 markers were previously considered related to or implicated in bladder cancer. These are the keratin family of proteins, some of which are known TCC markers, midkine, for which a single report ( PMID: 8653688) implies its connection to invasiveness in TCC; and FABP-5 which is related to squamous cell carcinoma of the bladder. A number of the other markers have been found to be related to other cancers, to varying extents. The specificity of markers for TCC over other cancers is an important consideration.

Four of the known up-regulated genes which are related to tumorigenesis are either membranal or secreted. Three of them were not previously reported in TCC, and the fourth (midkine) has been related to TCC invasiveness. Clearly, secreted and membranal proteins have a unique advantage for the development of a diagnostic test.

Intriguing amongst the functional group are markers related to keratinocyte differentiation. The keratins, which are cytoskeletal proteins, are known markers for keratinocyte differentiation. Five different keratins were detected in the top-scoring genes. Two of them are known to be TCC markers. The remaining three (KRT 7, 8, 17) were included in the 22 marker set. Expression of some of these and other keratins has been tested in the past by several research groups using different experimental approaches. Non-

consistent findings as to their regulation in TCC were reported. Thus, specific typing of the different keratins in urine of TCC patients, using a single multi-gene assay, can facilitate and improve robust TCC diagnostics.

A second major group of markers associated with keratinocyte differentiation are the S100 proteins. These are low-molecular-weight calcium-binding proteins which are probably involved in the regulation of a number of cellular processes including cell cycle progression and cell differentiation. Four different S100 proteins (S100A11, A6, A13,P) are included in the marker set. None has been previously associated with TCC. S100 proteins were implicated in other cancers (AML, colorectal). The S100P was found to be down-regulated upon androgen depletion in the androgen- dependent prostate cancer cell line LnCap. Another S100 protein, psoriasin (S100A7, not included in the set), is involved in both invasive breast cancer, squamous cell carcinoma of the bladder and psoriasis, another disease involving keratinocytes. Note, that another psoriasis-related gene, PA-FABP is also included in this proposed marker set. PA-FABP has also been implicated in squamous cell carcinoma of the bladder. Interactions between another FABP (E-FABP) and psoriasin are well-documented in psoriatic keratinocytes. The identified S100 proteins and PA-FABP are important novel markers for TCC.

### **Section 8. Sequence annotation of genes with identical expression pattern in all tested samples**

The diagnostic assay is based on the genes which are up-regulated in TCC. In all suggested tests, and mainly in the RT-PCR based assay, internal controls for each tested sample are beneficial. Such controls can be genes which are normally not upregulated in TCC. To this end the hybridization data was analyzed to identify genes which are:

1. Expressed at a high, easily detectable level in all the control and TCC samples. This is important to enable detection even in small amounts of RNA.
2. Genes which are not differential in TCC compared to normal urothelium. Such genes were specifically selected according to their normalized differentials 14 genes were detected as suitable according to these criteria (Section 9 hereunder). These genes are included in the diagnostic assays, and used as internal references for a normally, uniformly expressed gene in TCC and in non-TCC cases.

### **Section 9: Expression patterns, signals and annotation report for control genes**

The differential expression patterns and basic annotation for the 14 non-differential genes suggested as internal controls is provided in Table E (at

end of specification , just before Table 1). Table E displays differential expression results, and shows signals of all genes in all hybridizations.

The expression levels are shown in the following order:

Normal urothelium (16 first hybridizations)

T1 samples (13 hybridizations)

Ta samples (10 hybridizations).

All 14 clones were fully sequenced from both sides. Full (contigized) sequences passed via the standard sequence annotation platform including sequence QC, chimer detection, and homology searches within Genbank's non-redundant genomic and non-genomic nucleotide databases, the non-redundant protein database and the EST database. EST contigs were assembled for several novel genes for which ESTs were available, and further annotated.

The results supported the choice of any one, or a combination of two or more, of these 14 genes as internal controls.

## **Section 10. Class definition and characterization**

Staging and grading of TCC is not straightforward. In fact, subjective decisions must often be made in order to classify tumors, and pathological experts can differ on the correct diagnosis. Unsupervised analysis methods as well as supervised methods of class prediction were used, in order to reduce the dependence on expert opinion.

During the quality control process (section 2), some separation between T1 and Ta samples was noted in the third set of experiments, as well as in global clustering of all 41 profiles (39 normal or non-invasive, plus 2 invasive TCC samples). Therefore clustering of the tumor samples *within the third set only* (Table D1) was pursued. This set contains the largest and most variable collection of TCC samples. A clear differentiation exists between Ta and T1 tumors. One tumor classified as T1/Ta resides within the Ta cluster, but is separated from other Ta tumors. The two invasive tumor samples are in the T1 cluster (one clearly inside, the other outlying). Thus at the level of hierarchical clustering Ta tumors are separated from T1 high-grade tumors.

Standard scoring method (example 5, section 4) was employed for class prediction in order to identify specific molecular markers that underlie the Ta/T1 separation.

The Keratin 13 gene was found to be the highest scoring gene. It is down-regulated in T1 samples and up-regulated in Ta (relative to normal samples). Keratin 13 is known to be expressed in urothelium. Its expression in urothelial tumors depends on their degree of differentiation. It is expressed only in well-differentiated tumors and absent from poorly differentiated ones (PMID: 1706547). Since most of the Ta tumors in this set were classified as low grade while the T1 tumors were mostly high grade, over-expression of the KRT13 gene can be attributed to the degree of the differentiation as well as to the staging of the tumors.



The expression pattern of KRT13 in all TCC hybridizations was then studied. The results are not straightforward. Approximately half of the tumors show up-regulation of KRT13, while down-regulation is observed in others, with no clear correlation to either stage or grade of the tumor. KRT13 is highly relevant to the sub-classification of TCC tumors. However, the exact correlation to the classical clinical classifications remains to be elucidated in a larger set of tumors involving different stages and grades and in follow-up studies.

## **EXAMPLE 5: BIOINFORMATICS ANALYSIS OF 22**

### **SHORTLISTED GENES**

**1. Sequence** – All clones were fully sequenced from both sides. Sequence passed the standard sequence criteria, except where otherwise noted (see Table 6)

**2. Annotation** – Full (contigized) sequences were passed through the standard sequence annotation platform including sequence QC, chimera detection, and homology searches to Genbank's non-redundant genomic and non-genomic nucleotide databases, the non-redundant protein database and the EST database. EST contigs were assembled for several novel genes for which ESTs were available, and further annotated. Complete annotation and sequence information is available in Table 5.

**3. Literature** – an extensive search of the literature was performed for each of the known genes. Detailed information is given below.

Known genes are classified according to their function in tumorigenesis, keratinocyte differentiation, and cell motility and proliferation. References are given as PMIDs.

### **3.1 Genes associated with tumorigenesis**

#### **Genes coding for secreted and membranal proteins**

##### **3.1.1. Syndecan 1 (Accession: gi|4506858|ref|NM\_002997.1|)**

An integral membrane protein, 310 amino acid-long, with a signal peptide at its NH<sub>2</sub>-terminus. Contains a matrix-interacting ectodomain with putative glycosaminoglycan attachment sites, a hydrophobic membrane-spanning domain and a cytoplasmic domain. Is connected to cell aggregation in malignant mesotheliomas with epithelial and/or sarcomatous morphology and is required for wnt-1-induced mammary tumorigenesis in mice. On the other hand, its expression is inversely correlated to the aggressiveness of basal cell carcinoma. PMID: 2324102, 10912783, 10888884, 10770430.

##### **3.1.2. Hepatocyte growth factor activator inhibitor type 2 (HAI-2) (Accession: gi|2924619|dbj|AB006534.1|AB006534)**

HAI-2 is a Kunitz-type serine protease inhibitor which was recently identified as a potent inhibitor of hepatocyte growth factor activator. It was also independently reported as placental bikunin (PB) and as a protein over-expressed in pancreatic cancer. However, its expression was conserved in the neoplastic colorectal mucosa, and no relationship was found between HAI-2/PB mRNA levels and colorectal tumor stages. HAI-2 is produced in a membrane-

associated form and secreted in a proteolytically truncated form. PMID: .  
10695988 , 10762618

**3.1.3. Midkine (neurite growth promoting factor) (Accession:  
gi|4505134|ref|NM\_002391.1|)**

Midkine is a heparin-binding growth factor, implicated in various biological phenomena such as neuronal survival and differentiation, tissue remodeling and carcinogenesis. In the G401 cell line, midkine initiates a cascade of intracellular protein tyrosine phosphorylation mediated by the JAK/STAT pathway after binding to its high affinity p200(+)/MKR cell surface receptor. The most intriguing feature of midkine in cancer is its augmented expression in advanced tumors at a very high frequency in a non-tissue specific manner. In addition, its high expression is also detected in precancerous lesions. Midkine exerts carcinogenesis-related activities, including transforming, anti-apoptotic, angiogenic and fibrinolytic ones. These data provide a possibility of clinical application of midkine. Serum midkine level can be a useful tumor marker. Gene therapy using its promoter region and therapeutic strategy choosing midkine as a molecular target were also suggested. MK was suggested as a marker for early and latent bladder cancer disease (specificity of 0.86). Recent publication demonstrated good correlation of MK over-expression with poor outcome in patients with invasive cancers. PMID: 10879061, 8714367, 10902971, 10626184, 10545795, 10408712

#### 3.1.4. Solute carrier family 2 SLC2A1 (GLUT1) (Accession:

gi|5730050|ref|NM\_006516.1|)

Increased expression of glucose transporter1 (GLUT1) has been reported in many human cancers. Suppression of GLUT1 mRNA has been shown to suppress tumor growth. Some studies have reported associations between its expression and proliferative indices, whilst others suggest that GLUT1 can be of prognostic significance, especially in lung cancer. No connection between GLUT1 up-regulation and TCC has yet been reported. PMID: 10983690, 10806305, 10795374.

#### Genes coding for intracellular proteins

#### 3.1.5. Cystatin B (Accession:

gi|7263011|gb|AF208234.1|AF208234)

Cystatins are endogenous inhibitors of lysosomal cysteine proteinases, the cathepsins (Cats). Imbalance between cathepsins and cystatins, associated with metastatic tumor cell phenotype, can facilitate tumor cell invasion and metastasis. Cystatins were found to be up-regulated in relation to inflammation and cancer (breast, lung, brain and head and neck tumors, and in body fluids of ovarian, uterine, melanoma and colorectal carcinoma). In contrast, reduced expression of cystatin B was found in esophageal-carcinoma tissue and was associated with lymph-node metastasis. The application of cystatins for prognosis, diagnosis, follow-up and anticancer therapy has been proposed (but not for TCC). In the preliminary experiments in TCC, using general microarray

containing 10,000 human ESTs, Cystatin A was found to be up-regulated in TCC pool compared to pool of normals. **PMID: 10566975, 9769367, 9583733,10514828.**

### 3.1.5 Opa-interacting protein OIP3

(Accession:gi|2815605|gb|AF025439.1|AF025439)

Opa proteins are a family of outer membrane proteins involved in gonococcal adherence to and invasion of human cells. Pyruvate kinase M2 is OIP3 which binds to OPA proteins. Modulation of type M2 pyruvate kinase activity by the human papillomavirus type 16 E7 oncoprotein has been demonstrated. PMID: 9990017, 9692838

## **3.2 Genes associated with abnormal differentiation of keratinocytes**

### **3.2.1. Keratins: keratin 19, keratin 7, keratin 8, keratin 18, keratin 17**

Keratins, or cytokeratins, represent a family of more than 20 different polypeptides which are important markers of epithelial cell differentiation. Both gene expression and protein levels are elevated (and even used as a marker) in several pathological conditions including breast cancer, kidney tumors, small cell lung cancer (SCLC), and pre-eclampsia. Measurements of cytokeratins 19 and 20 levels in serum and urine are in use as tumor marker for bladder cancers.

Keratin 18 is a type-I keratin that is found in a variety of simple epithelial tissues. Pancreatic exocrine acinar cells and endocrine islet cells are well-differentiated cells which express the keratin combination 8 and 18, whereas the less-differentiated cells of the ductal tree are characterized by the additional expression of keratin 7, keratin 19, and, in the rat, keratin 20. Levels of keratin 7 and 20 are increased in rectal adenocarcinoma and Paget's disease. PMID: 10755601, 10707834, 10782894, 10775728, 10762743, 9614373, 8911513, 9445193, 2434380

### **3.2.2. S100 proteins: S100A11, S100P, S100 Calcium binding protein A13, S100A6**

S100 proteins are low-molecular-weight calcium-binding proteins of the EF-hand superfamily and appear to be involved in the regulation of a number of cellular processes such as cell cycle progression and differentiation. More than 10 members of the S100 protein family have been described from human sources so far. Induced expression in tumors of some of these genes has been reported.

S100A11 (or S100C/ Calgizzarin)

Calgizzarin is a nuclear protein which inhibits the actin-activated myosin Mg(2+)-ATPase activity of smooth muscle in a dose-dependent manner. Other Ca(2+)-binding proteins such as S100A1, S100A2, S100B, and calmodulin do not inhibit actin-activated myosin Mg(2+)-ATPase activity. Calgizzarin can be involved in the regulation of actin-activated myosin Mg(2+)-ATPase activity

through its  $\text{Ca}^{2+}$ -dependent interaction with actin filaments. It is expressed in most tissues and cell lines, and co-localized with the psoriasis gene S100A7 and other S100 genes to human chromosome 1q21-q22.

Calgizzarin was found to be remarkably elevated in colorectal cancers compared with that in normal colorectal mucosa. No similar alteration in expression was detected in breast cancer. PMID: 10486266, 10623577, 7591220, 7889529

S100P (Accession: gi|5174662|ref|NM\_005980.1|)

S100P overexpression is an early event that might play an important role in the immortalization of human breast epithelial cells in vitro and tumor progression in vivo. S100P expression was downregulated after removal of androgen from LnCAP prostate cancer cell line. PMID: 10639564, 8977631

S100 Calcium binding protein A13

(Accession: gi|5174658|ref|NM\_005979.1|)

S100A13 was found to be widely expressed in various types of tissues including skeletal muscle, heart, kidney, ovary, small intestine and pancreas. It was shown to bind anti-allergic drugs and thus to be involved in the inhibition of degranulation of mast cells. Also, it was shown to be involved in the regulation of FGF1 activity. PMID: 10722710, 8878558, 9712836, 10051426

### **Growth factor inducible 2a9/calcyclin/S100A6 (Accession:**

**M14300)**

2A9 was isolated from stimulated quiescent fibroblasts. It is induced by growth factors and over-expressed in AML. S100A6 was also suggested to be involved in the progression and invasive process of human colorectal adenocarcinomas. PMID: 10656447, 1952954

### **3.2.3 PA-FABP - Fatty acid binding protein 5 (psoriasis-associated)**

(Accession: gi|4557580|ref|NM\_001444.1|)

The fatty acid-binding protein (FABP) family consists of small, cytosolic proteins believed to be involved in the uptake, transport, and solubilization of their hydrophobic ligands. PA-FBP can be involved in keratinocyte differentiation. In normal skin, PA-FABP is expressed in basal and prickle cell layers, and more strongly in the granular cell layer. In psoriatic skin, PA-FABP is expressed in suprabasal layers and more strongly in more differentiated keratinocytes. In squamous cell carcinoma, PA-FABP shows very strong expression in squamous nests. Serum levels of intestinal fatty acid-binding protein (I-FABP) serve as diagnostic marker for mesenteric infarction (acute ischemic diseases of the bowel). Expression of PA-FABP has been linked to squamous cell carcinoma of the bladder. PMID: 9521644, 9438903, 8566578, 8092987, 9307301



### **3.3 Genes involved in cell motility and proliferation**

#### **3.3.1 Actin gamma 1 (Accession: gi|4501886|ref|NM\_001614.1| gi|4501886|ref|NM\_001614.1|)**

Ubiquitously expressed in all eukaryotic cells. Beta and gamma actins co-exist in most cell types as components of the cytoskeleton and as mediators of internal cell motility.

#### **3.3.2 37 kD laminin receptor precursor/p40 ribosome associated protein**

**(Accession: HSU43901)**

The 37 kD precursor of the 67 kD laminin receptor (37LRP) is a polypeptide whose expression is consistently up-regulated in aggressive carcinoma. Interestingly, the 37LRP appears to be a multifunctional protein involved in the translational machinery and has also been identified as p40 ribosome-associated protein. It is distributed on the cell surface as laminin binding protein p67 (LBP/p67), in the nucleus, and on 40S ribosomes. PMID: 8760291, 10079194

Throughout this application, various publications, including United States patents, are referenced by author and year and patents by number. Full citations for the publications are listed below. The disclosures of these publications and patents in their entireties are hereby incorporated by reference

into this application in order to more fully describe the state of the art to which this invention pertains.

The invention has been described in an illustrative manner, and it is to be understood that the terminology which has been used is intended to be in the nature of words of description rather than of limitation.

Obviously, many modifications and variations of the present invention are possible in light of the above teachings. It is, therefore, to be understood that within the scope of the described invention, the invention can be practiced otherwise than as specifically described.

Table E

Index	GeneDescription1	Acc1	GeneID	TC7	TC8	TC9	TC10	TC11	TC12	TC21	TC22	TC23	TC24	TC31	TC32	TC33	TC34	TC35	TC36	TC37	TC38	TC39	TC40	TC41	TC42	TC43	TC44	TC45	TC46	TC47	TC48	TC49	TC50	TC51	TC52	TC53	TC54	TC55	TC56	TC57	TC58	TC59	TC60	TC61	TC62	TC63	TC64	TC65	TC66	TC67	TC68	TC69	TC70	TC71	TC72	TC73	TC74	TC75	TC76	TC77	TC78	TC79	TC80	TC81	TC82	TC83	TC84	TC85	TC86	TC87	TC88	TC89	TC90	TC91	TC92	TC93	TC94	TC95	TC96	TC97	TC98	TC99	TC100	TC101	TC102	TC103	TC104	TC105	TC106	TC107	TC108	TC109	TC110	TC111	TC112	TC113	TC114	TC115	TC116	TC117	TC118	TC119	TC120	TC121	TC122	TC123	TC124	TC125	TC126	TC127	TC128	TC129	TC130	TC131	TC132	TC133	TC134	TC135	TC136	TC137	TC138	TC139	TC140	TC141	TC142	TC143	TC144	TC145	TC146	TC147	TC148	TC149	TC150	TC151	TC152	TC153	TC154	TC155	TC156	TC157	TC158	TC159	TC160	TC161	TC162	TC163	TC164	TC165	TC166	TC167	TC168	TC169	TC170	TC171	TC172	TC173	TC174	TC175	TC176	TC177	TC178	TC179	TC180	TC181	TC182	TC183	TC184	TC185	TC186	TC187	TC188	TC189	TC190	TC191	TC192	TC193	TC194	TC195	TC196	TC197	TC198	TC199	TC200	TC201	TC202	TC203	TC204	TC205	TC206	TC207	TC208	TC209	TC210	TC211	TC212	TC213	TC214	TC215	TC216	TC217	TC218	TC219	TC220	TC221	TC222	TC223	TC224	TC225	TC226	TC227	TC228	TC229	TC230	TC231	TC232	TC233	TC234	TC235	TC236	TC237	TC238	TC239	TC240	TC241	TC242	TC243	TC244	TC245	TC246	TC247	TC248	TC249	TC250	TC251	TC252	TC253	TC254	TC255	TC256	TC257	TC258	TC259	TC260	TC261	TC262	TC263	TC264	TC265	TC266	TC267	TC268	TC269	TC270	TC271	TC272	TC273	TC274	TC275	TC276	TC277	TC278	TC279	TC280	TC281	TC282	TC283	TC284	TC285	TC286	TC287	TC288	TC289	TC290	TC291	TC292	TC293	TC294	TC295	TC296	TC297	TC298	TC299	TC300	TC301	TC302	TC303	TC304	TC305	TC306	TC307	TC308	TC309	TC310	TC311	TC312	TC313	TC314	TC315	TC316	TC317	TC318	TC319	TC320	TC321	TC322	TC323	TC324	TC325	TC326	TC327	TC328	TC329	TC330	TC331	TC332	TC333	TC334	TC335	TC336	TC337	TC338	TC339	TC340	TC341	TC342	TC343	TC344	TC345	TC346	TC347	TC348	TC349	TC350	TC351	TC352	TC353	TC354	TC355	TC356	TC357	TC358	TC359	TC360	TC361	TC362	TC363	TC364	TC365	TC366	TC367	TC368	TC369	TC370	TC371	TC372	TC373	TC374	TC375	TC376	TC377	TC378	TC379	TC380	TC381	TC382	TC383	TC384	TC385	TC386	TC387	TC388	TC389	TC390	TC391	TC392	TC393	TC394	TC395	TC396	TC397	TC398	TC399	TC400	TC401	TC402	TC403	TC404	TC405	TC406	TC407	TC408	TC409	TC410	TC411	TC412	TC413	TC414	TC415	TC416	TC417	TC418	TC419	TC420	TC421	TC422	TC423	TC424	TC425	TC426	TC427	TC428	TC429	TC430	TC431	TC432	TC433	TC434	TC435	TC436	TC437	TC438	TC439	TC440	TC441	TC442	TC443	TC444	TC445	TC446	TC447	TC448	TC449	TC450	TC451	TC452	TC453	TC454	TC455	TC456	TC457	TC458	TC459	TC460	TC461	TC462	TC463	TC464	TC465	TC466	TC467	TC468	TC469	TC470	TC471	TC472	TC473	TC474	TC475	TC476	TC477	TC478	TC479	TC480	TC481	TC482	TC483	TC484	TC485	TC486	TC487	TC488	TC489	TC490	TC491	TC492	TC493	TC494	TC495	TC496	TC497	TC498	TC499	TC500	TC501	TC502	TC503	TC504	TC505	TC506	TC507	TC508	TC509	TC510	TC511	TC512	TC513	TC514	TC515	TC516	TC517	TC518	TC519	TC520	TC521	TC522	TC523	TC524	TC525	TC526	TC527	TC528	TC529	TC530	TC531	TC532	TC533	TC534	TC535	TC536	TC537	TC538	TC539	TC540	TC541	TC542	TC543	TC544	TC545	TC546	TC547	TC548	TC549	TC550	TC551	TC552	TC553	TC554	TC555	TC556	TC557	TC558	TC559	TC560	TC561	TC562	TC563	TC564	TC565	TC566	TC567	TC568	TC569	TC570	TC571	TC572	TC573	TC574	TC575	TC576	TC577	TC578	TC579	TC580	TC581	TC582	TC583	TC584	TC585	TC586	TC587	TC588	TC589	TC590	TC591	TC592	TC593	TC594	TC595	TC596	TC597	TC598	TC599	TC600	TC601	TC602	TC603	TC604	TC605	TC606	TC607	TC608	TC609	TC610	TC611	TC612	TC613	TC614	TC615	TC616	TC617	TC618	TC619	TC620	TC621	TC622	TC623	TC624	TC625	TC626	TC627	TC628	TC629	TC630	TC631	TC632	TC633	TC634	TC635	TC636	TC637	TC638	TC639	TC640	TC641	TC642	TC643	TC644	TC645	TC646	TC647	TC648	TC649	TC650	TC651	TC652	TC653	TC654	TC655	TC656	TC657	TC658	TC659	TC660	TC661	TC662	TC663	TC664	TC665	TC666	TC667	TC668	TC669	TC670	TC671	TC672	TC673	TC674	TC675	TC676	TC677	TC678	TC679	TC680	TC681	TC682	TC683	TC684	TC685	TC686	TC687	TC688	TC689	TC690	TC691	TC692	TC693	TC694	TC695	TC696	TC697	TC698	TC699	TC700	TC701	TC702	TC703	TC704	TC705	TC706	TC707	TC708	TC709	TC710	TC711	TC712	TC713	TC714	TC715	TC716	TC717	TC718	TC719	TC720	TC721	TC722	TC723	TC724	TC725	TC726	TC727	TC728	TC729	TC730	TC731	TC732	TC733	TC734	TC735	TC736	TC737	TC738	TC739	TC740	TC741	TC742	TC743	TC744	TC745	TC746	TC747	TC748	TC749	TC750	TC751	TC752	TC753	TC754	TC755	TC756	TC757	TC758	TC759	TC760	TC761	TC762	TC763	TC764	TC765	TC766	TC767	TC768	TC769	TC770	TC771	TC772	TC773	TC774	TC775	TC776	TC777	TC778	TC779	TC780	TC781	TC782	TC783	TC784	TC785	TC786	TC787	TC788	TC789	TC790	TC791	TC792	TC793	TC794	TC795	TC796	TC797	TC798	TC799	TC800	TC801	TC802	TC803	TC804	TC805	TC806	TC807	TC808	TC809	TC810	TC811	TC812	TC813	TC814	TC815	TC816	TC817	TC818	TC819	TC820	TC821	TC822	TC823	TC824	TC825	TC826	TC827	TC828	TC829	TC830	TC831	TC832	TC833	TC834	TC835	TC836	TC837	TC838	TC839	TC840	TC841	TC842	TC843	TC844	TC845	TC846	TC847	TC848	TC849	TC850	TC851	TC852	TC853	TC854	TC855	TC856	TC857	TC858	TC859	TC860	TC861	TC862	TC863	TC864	TC865	TC866	TC867	TC868	TC869	TC870	TC871	TC872	TC873	TC874	TC875	TC876	TC877	TC878	TC879	TC880	TC881	TC882	TC883	TC884	TC885	TC886	TC887	TC888	TC889	TC890	TC891	TC892	TC893	TC894	TC895	TC896	TC897	TC898	TC899	TC900	TC901	TC902	TC903	TC904	TC905	TC906	TC907	TC908	TC909	TC910	TC911	TC912	TC913	TC914	TC915	TC916	TC917	TC918	TC919	TC920	TC921	TC922	TC923	TC924	TC925	TC926	TC927	TC928	TC929	TC930	TC931	TC932	TC933	TC934	TC935	TC936	TC937	TC938	TC939	TC940	TC941	TC942	TC943	TC944	TC945	TC946	TC947	TC948	TC949	TC950	TC951	TC952	TC953	TC954	TC955	TC956	TC957	TC958	TC959	TC960	TC961	TC962	TC963	TC964	TC965	TC966	TC967	TC968	TC969	TC970	TC971	TC972	TC973	TC974	TC975	TC976	TC977	TC978	TC979	TC980	TC981	TC982	TC983	TC984	TC985	TC986	TC987	TC988	TC989	TC990	TC991	TC992	TC993	TC994	TC995	TC996	TC997	TC998	TC999	TC1000	TC1001	TC1002	TC1003	TC1004	TC1005	TC1006	TC1007	TC1008	TC1009	TC1010	TC1011	TC1012	TC1013	TC1014	TC1015	TC1016	TC1017	TC1018	TC1019	TC1020	TC1021	TC1022	TC1023	TC1024	TC1025	TC1026	TC1027	TC1028	TC1029	TC1030	TC1031	TC1032	TC1033	TC1034	TC1035	TC1036	TC1037	TC1038	TC1039	TC1040	TC1041	TC1042	TC1043	TC1044	TC1045	TC1046	TC1047	TC1048	TC1049	TC1050	TC1051	TC1052	TC1053	TC1054	TC1055	TC1056	TC1057	TC1058	TC1059	TC1060	TC1061	TC1062	TC1063	TC1064	TC1065	TC1066	TC1067	TC1068	TC1069	TC1070	TC1071	TC1072	TC1073	TC1074	TC1075	TC1076	TC1077	TC1078	TC1079	TC1080	TC1081	TC1082	TC1083	TC1084	TC1085	TC1086	TC1087	TC1088	TC1089	TC1090	TC1091	TC1092	TC1093	TC1094	TC1095	TC1096	TC1097	TC1098	TC1099	TC1100	TC1101	TC1102	TC1103	TC1104	TC1105	TC1106	TC1107	TC1108	TC1109	TC1110	TC1111	TC1112	TC1113	TC1114	TC1115	TC1116	TC1117	TC1118	TC1119	TC1120	TC1121	TC1122	TC1123	TC1124	TC1125	TC1126	TC1127	TC1128	TC1129	TC1130	TC1131	TC1132	TC1133	TC1134	TC1135	TC1136	TC1137	TC1138	TC1139	TC1140	TC1141	TC1142	TC1143	TC1144	TC1145	TC1146	TC1147	TC1148	TC1149	TC1150	TC1151	TC1152	TC1153	TC1154	TC1155	TC1156	TC1157	TC1158	TC1159	TC1160	TC1161	TC1162	TC1163	TC1164	TC1165	TC1166	TC1167	TC1168	TC1169	TC1170	TC1171	TC1172	TC1173	TC1174	TC1175	TC1176	TC1177	TC1178	TC1179	TC1180	TC1181	TC1182	TC1183	TC1184	TC1185	TC1186	TC1187	TC1188	TC1189	TC1190	TC1191	TC1192	TC1193	TC1194	TC1195	TC1196	TC1197	TC1198	TC1199	TC1200	TC1201	TC1202	TC1203	TC1204	TC1205	TC1206	TC1207	TC1208	TC1209	TC1210	TC1211	TC1212	TC1213	TC1214	TC1215	TC1216	TC1217	TC1218	TC1219	TC1220	TC1221	TC1222	TC1223	TC1224	TC1225	TC1226	TC1227	TC1228	TC1229	TC1230	TC1231	TC1232	TC1233	TC1234	TC1235	TC1236	TC1237	TC1238	TC1239	TC1240	TC1241	TC1242	TC1243	TC1244	TC1245	TC1246	TC1247	TC1248	TC1249	TC1250	TC1251	TC1252	TC1253	TC1254	TC1255	TC1256	TC1257	TC1258	TC1259	TC1260	TC1261	TC1262	TC1263	TC1264	TC1265	TC1266	TC1267	TC1268	TC1269	TC1270	TC1271	TC1272	TC1273	TC1274	TC1275	TC1276	TC1277	TC1278	TC1279	TC1280	TC1281	TC1282	TC1283	TC1284	TC1285	TC1286	TC1287	TC1288	TC1289	TC1290	TC1291	TC1292	TC1293	TC1294	TC1295	TC1296	TC1297	TC1298	TC1299	TC1300	TC1301	TC1302	TC1303	TC1304	TC1305	TC1306	TC1307	TC1308	TC1309	TC1310	TC1311	TC1312	TC1313	TC1314	TC1315	TC1316	TC1317	TC1318	TC1319	TC1320	TC1321	TC1322	TC1323	TC1324	TC1325	TC1326	TC1327	TC1328	TC1329	TC1330	TC1331	TC1332	TC1333	TC1334	TC1335	TC1336	TC1337	TC1338	TC1339	TC1340	TC1341	TC1342	TC1343	TC1344	TC1345	TC1346	TC1347	TC1348	TC1349	TC135
-------	------------------	------	--------	-----	-----	-----	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	-------

Table E

TC2	TC3	TC4	TC5	TC6	TC16	TC17	TC18	TC19	TC20	TC21	TC22	TC23	TC24	TC25	TC26	TC27	TC28	TC29	TC30	TC31	TC32	TC33	TC34	TC35	TC36	TC37	TC38	TC39	TC40	TC41	TC42	TC43	TC44	TC45	TC46	TC47	TC48	TC49	TC50	TC51	TC52	TC53	TC54	TC55	TC56	TC57	TC58	TC59	TC60	TC61	TC62	TC63	TC64	TC65	TC66	TC67	TC68	TC69	TC70	TC71	TC72	TC73	TC74	TC75	TC76	TC77	TC78	TC79	TC80	TC81	TC82	TC83	TC84	TC85	TC86	TC87	TC88	TC89	TC90	TC91	TC92	TC93	TC94	TC95	TC96	TC97	TC98	TC99	TC100	TC101	TC102	TC103	TC104	TC105	TC106	TC107	TC108	TC109	TC110	TC111	TC112	TC113	TC114	TC115	TC116	TC117	TC118	TC119	TC120	TC121	TC122	TC123	TC124	TC125	TC126	TC127	TC128	TC129	TC130	TC131	TC132	TC133	TC134	TC135	TC136	TC137	TC138	TC139	TC140	TC141	TC142	TC143	TC144	TC145	TC146	TC147	TC148	TC149	TC150	TC151	TC152	TC153	TC154	TC155	TC156	TC157	TC158	TC159	TC160	TC161	TC162	TC163	TC164	TC165	TC166	TC167	TC168	TC169	TC170	TC171	TC172	TC173	TC174	TC175	TC176	TC177	TC178	TC179	TC180	TC181	TC182	TC183	TC184	TC185	TC186	TC187	TC188	TC189	TC190	TC191	TC192	TC193	TC194	TC195	TC196	TC197	TC198	TC199	TC200	TC201	TC202	TC203	TC204	TC205	TC206	TC207	TC208	TC209	TC210	TC211	TC212	TC213	TC214	TC215	TC216	TC217	TC218	TC219	TC220	TC221	TC222	TC223	TC224	TC225	TC226	TC227	TC228	TC229	TC230	TC231	TC232	TC233	TC234	TC235	TC236	TC237	TC238	TC239	TC240	TC241	TC242	TC243	TC244	TC245	TC246	TC247	TC248	TC249	TC250	TC251	TC252	TC253	TC254	TC255	TC256	TC257	TC258	TC259	TC260	TC261	TC262	TC263	TC264	TC265	TC266	TC267	TC268	TC269	TC270	TC271	TC272	TC273	TC274	TC275	TC276	TC277	TC278	TC279	TC280	TC281	TC282	TC283	TC284	TC285	TC286	TC287	TC288	TC289	TC290	TC291	TC292	TC293	TC294	TC295	TC296	TC297	TC298	TC299	TC300	TC301	TC302	TC303	TC304	TC305	TC306	TC307	TC308	TC309	TC310	TC311	TC312	TC313	TC314	TC315	TC316	TC317	TC318	TC319	TC320	TC321	TC322	TC323	TC324	TC325	TC326	TC327	TC328	TC329	TC330	TC331	TC332	TC333	TC334	TC335	TC336	TC337	TC338	TC339	TC340	TC341	TC342	TC343	TC344	TC345	TC346	TC347	TC348	TC349	TC350	TC351	TC352	TC353	TC354	TC355	TC356	TC357	TC358	TC359	TC360	TC361	TC362	TC363	TC364	TC365	TC366	TC367	TC368	TC369	TC370	TC371	TC372	TC373	TC374	TC375	TC376	TC377	TC378	TC379	TC380	TC381	TC382	TC383	TC384	TC385	TC386	TC387	TC388	TC389	TC390	TC391	TC392	TC393	TC394	TC395	TC396	TC397	TC398	TC399	TC400	TC401	TC402	TC403	TC404	TC405	TC406	TC407	TC408	TC409	TC410	TC411	TC412	TC413	TC414	TC415	TC416	TC417	TC418	TC419	TC420	TC421	TC422	TC423	TC424	TC425	TC426	TC427	TC428	TC429	TC430	TC431	TC432	TC433	TC434	TC435	TC436	TC437	TC438	TC439	TC440	TC441	TC442	TC443	TC444	TC445	TC446	TC447	TC448	TC449	TC450	TC451	TC452	TC453	TC454	TC455	TC456	TC457	TC458	TC459	TC460	TC461	TC462	TC463	TC464	TC465	TC466	TC467	TC468	TC469	TC470	TC471	TC472	TC473	TC474	TC475	TC476	TC477	TC478	TC479	TC480	TC481	TC482	TC483	TC484	TC485	TC486	TC487	TC488	TC489	TC490	TC491	TC492	TC493	TC494	TC495	TC496	TC497	TC498	TC499	TC500	TC501	TC502	TC503	TC504	TC505	TC506	TC507	TC508	TC509	TC510	TC511	TC512	TC513	TC514	TC515	TC516	TC517	TC518	TC519	TC520	TC521	TC522	TC523	TC524	TC525	TC526	TC527	TC528	TC529	TC530	TC531	TC532	TC533	TC534	TC535	TC536	TC537	TC538	TC539	TC540	TC541	TC542	TC543	TC544	TC545	TC546	TC547	TC548	TC549	TC550	TC551	TC552	TC553	TC554	TC555	TC556	TC557	TC558	TC559	TC560	TC561	TC562	TC563	TC564	TC565	TC566	TC567	TC568	TC569	TC570	TC571	TC572	TC573	TC574	TC575	TC576	TC577	TC578	TC579	TC580	TC581	TC582	TC583	TC584	TC585	TC586	TC587	TC588	TC589	TC590	TC591	TC592	TC593	TC594	TC595	TC596	TC597	TC598	TC599	TC600	TC601	TC602	TC603	TC604	TC605	TC606	TC607	TC608	TC609	TC610	TC611	TC612	TC613	TC614	TC615	TC616	TC617	TC618	TC619	TC620	TC621	TC622	TC623	TC624	TC625	TC626	TC627	TC628	TC629	TC630	TC631	TC632	TC633	TC634	TC635	TC636	TC637	TC638	TC639	TC640	TC641	TC642	TC643	TC644	TC645	TC646	TC647	TC648	TC649	TC650	TC651	TC652	TC653	TC654	TC655	TC656	TC657	TC658	TC659	TC660	TC661	TC662	TC663	TC664	TC665	TC666	TC667	TC668	TC669	TC670	TC671	TC672	TC673	TC674	TC675	TC676	TC677	TC678	TC679	TC680	TC681	TC682	TC683	TC684	TC685	TC686	TC687	TC688	TC689	TC690	TC691	TC692	TC693	TC694	TC695	TC696	TC697	TC698	TC699	TC700	TC701	TC702	TC703	TC704	TC705	TC706	TC707	TC708	TC709	TC710	TC711	TC712	TC713	TC714	TC715	TC716	TC717	TC718	TC719	TC720	TC721	TC722	TC723	TC724	TC725	TC726	TC727	TC728	TC729	TC730	TC731	TC732	TC733	TC734	TC735	TC736	TC737	TC738	TC739	TC740	TC741	TC742	TC743	TC744	TC745	TC746	TC747	TC748	TC749	TC750	TC751	TC752	TC753	TC754	TC755	TC756	TC757	TC758	TC759	TC760	TC761	TC762	TC763	TC764	TC765	TC766	TC767	TC768	TC769	TC770	TC771	TC772	TC773	TC774	TC775	TC776	TC777	TC778	TC779	TC780	TC781	TC782	TC783	TC784	TC785	TC786	TC787	TC788	TC789	TC790	TC791	TC792	TC793	TC794	TC795	TC796	TC797	TC798	TC799	TC800	TC801	TC802	TC803	TC804	TC805	TC806	TC807	TC808	TC809	TC810	TC811	TC812	TC813	TC814	TC815	TC816	TC817	TC818	TC819	TC820	TC821	TC822	TC823	TC824	TC825	TC826	TC827	TC828	TC829	TC830	TC831	TC832	TC833	TC834	TC835	TC836	TC837	TC838	TC839	TC840	TC841	TC842	TC843	TC844	TC845	TC846	TC847	TC848	TC849	TC850	TC851	TC852	TC853	TC854	TC855	TC856	TC857	TC858	TC859	TC860	TC861	TC862	TC863	TC864	TC865	TC866	TC867	TC868	TC869	TC870	TC871	TC872	TC873	TC874	TC875	TC876	TC877	TC878	TC879	TC880	TC881	TC882	TC883	TC884	TC885	TC886	TC887	TC888	TC889	TC890	TC891	TC892	TC893	TC894	TC895	TC896	TC897	TC898	TC899	TC900	TC901	TC902	TC903	TC904	TC905	TC906	TC907	TC908	TC909	TC910	TC911	TC912	TC913	TC914	TC915	TC916	TC917	TC918	TC919	TC920	TC921	TC922	TC923	TC924	TC925	TC926	TC927	TC928	TC929	TC930	TC931	TC932	TC933	TC934	TC935	TC936	TC937	TC938	TC939	TC940	TC941	TC942	TC943	TC944	TC945	TC946	TC947	TC948	TC949	TC950	TC951	TC952	TC953	TC954	TC955	TC956	TC957	TC958	TC959	TC960	TC961	TC962	TC963	TC964	TC965	TC966	TC967	TC968	TC969	TC970	TC971	TC972	TC973	TC974	TC975	TC976	TC977	TC978	TC979	TC980	TC981	TC982	TC983	TC984	TC985	TC986	TC987	TC988	TC989	TC990	TC991	TC992	TC993	TC994	TC995	TC996	TC997	TC998	TC999	TC1000	TC1001	TC1002	TC1003	TC1004	TC1005	TC1006	TC1007	TC1008	TC1009	TC1010	TC1011	TC1012	TC1013	TC1014	TC1015	TC1016	TC1017	TC1018	TC1019	TC1020	TC1021	TC1022	TC1023	TC1024	TC1025	TC1026	TC1027	TC1028	TC1029	TC1030	TC1031	TC1032	TC1033	TC1034	TC1035	TC1036	TC1037	TC1038	TC1039	TC1040	TC1041	TC1042	TC1043	TC1044	TC1045	TC1046	TC1047	TC1048	TC1049	TC1050	TC1051	TC1052	TC1053	TC1054	TC1055	TC1056	TC1057	TC1058	TC1059	TC1060	TC1061	TC1062	TC1063	TC1064	TC1065	TC1066	TC1067	TC1068	TC1069	TC1070	TC1071	TC1072	TC1073	TC1074	TC1075	TC1076	TC1077	TC1078	TC1079	TC1080	TC1081	TC1082	TC1083	TC1084	TC1085	TC1086	TC1087	TC1088	TC1089	TC1090	TC1091	TC1092	TC1093	TC1094	TC1095	TC1096	TC1097	TC1098	TC1099	TC1100	TC1101	TC1102	TC1103	TC1104	TC1105	TC1106	TC1107	TC1108	TC1109	TC1110	TC1111	TC1112	TC1113	TC1114	TC1115	TC1116	TC1117	TC1118	TC1119	TC1120	TC1121	TC1122	TC1123	TC1124	TC1125	TC1126	TC1127	TC1128	TC1129	TC1130	TC1131	TC1132	TC1133	TC1134	TC1135	TC1136	TC1137	TC1138	TC1139	TC1140	TC1141	TC1142	TC1143	TC1144	TC1145	TC1146	TC1147	TC1148	TC1149	TC1150	TC1151	TC1152	TC1153	TC1154	TC1155	TC1156	TC1157	TC1158	TC1159	TC1160	TC1161	TC1162	TC1163	TC1164	TC1165	TC1166	TC1167	TC1168	TC1169	TC1170	TC1171	TC1172	TC1173	TC1174	TC1175	TC1176	TC1177	TC1178	TC1179	TC1180	TC1181	TC1182	TC1183	TC1184	TC1185	TC1186	TC1187	TC1188	TC1189	TC1190	TC1191	TC1192	TC1193	TC1194	TC1195	TC1196	TC1197	TC1198	TC1199	TC1200	TC1201	TC1202	TC1203	TC1204	TC1205	TC1206	TC1207	TC1208	TC1209	TC1210	TC1211	TC1212	TC1213	TC1214	TC1215	TC1216	TC1217	TC1218	TC1219	TC1220	TC1221	TC1222	TC1223	TC1224	TC1225	TC1226	TC1227	TC1228	TC1229	TC1230	TC1231	TC1232	TC1233	TC1234	TC1235	TC1236	TC1237	TC1238	TC1239	TC1240	TC1241	TC1242	TC1243	TC1244	TC1245	TC1246	TC1247	TC1248	TC1249	TC1250	TC1251	TC1252	TC1253	TC1254	TC1255	TC1256	TC1257	TC1258	TC1259	TC1260	TC1261	TC1262	TC1263	TC1264	TC1265	TC1266	TC1267	TC1268	TC1269	TC1270	TC1271	TC1272	TC1273	TC1274	TC1275	TC1276	TC1277	TC1278	TC1279	TC1280	TC1281	TC1282	TC1283	TC1284	TC1285	TC1286	TC1287	TC1288	TC1289	TC1290	TC1291	TC1292	TC1293	TC1294	TC1295	TC1296	TC1297	TC1298	TC1299	TC1300	TC1301	TC1302	TC1303	TC1304	TC1305	TC1306	TC1307	TC1308	TC1309	TC1310	TC1311	TC1312	TC1313	TC1314	TC1315	TC1316	TC1317	TC1318	TC1319	TC1320	TC1321	TC1322	TC1323	TC1324	TC1325	TC1326	TC1327	TC1328	TC1329	TC1330	TC1331	TC1332	TC1333	TC1334	TC1335	TC1336	TC1337	TC1338	TC1339	TC1340	TC1341	TC1342	TC1343	TC1344	TC13
-----	-----	-----	-----	-----	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	------

TABLE 1

TABLE 1		Accession		2022		2023		2024		2025		2026		2027		2028		2029		2030		2031		2032		2033		2034		2035		2036		2037		2038		2039		2040		2041		2042		2043		2044		2045		2046		2047		2048		2049		2050		2051		2052		2053		2054		2055		2056		2057		2058		2059		2060		2061		2062		2063		2064		2065		2066		2067		2068		2069		2070		2071		2072		2073		2074		2075		2076		2077		2078		2079		2080		2081		2082		2083		2084		2085		2086		2087		2088		2089		2090		2091		2092		2093		2094		2095		2096		2097		2098		2099		2100		2101		2102		2103		2104		2105		2106		2107		2108		2109		2110		2111		2112		2113		2114		2115		2116		2117		2118		2119		2120		2121		2122		2123		2124		2125		2126		2127		2128		2129		2130		2131		2132		2133		2134		2135		2136		2137		2138		2139		2140		2141		2142		2143		2144		2145		2146		2147		2148		2149		2150		2151		2152		2153		2154		2155		2156		2157		2158		2159		2160		2161		2162		2163		2164		2165		2166		2167		2168		2169		2170		2171		2172		2173		2174		2175		2176		2177		2178		2179		2180		2181		2182		2183		2184		2185		2186		2187		2188		2189		2190		2191		2192		2193		2194		2195		2196		2197		2198		2199		2200		2201		2202		2203		2204		2205		2206		2207		2208		2209		2210		2211		2212		2213		2214		2215		2216		2217		2218		2219		2220		2221		2222		2223		2224		2225		2226		2227		2228		2229		2230		2231		2232		2233		2234		2235		2236		2237		2238		2239		2240		2241		2242		2243		2244		2245		2246		2247		2248		2249		2250		2251		2252		2253		2254		2255		2256		2257		2258		2259		2260		2261		2262		2263		2264		2265		2266		2267		2268		2269		2270		2271		2272		2273		2274		2275		2276		2277		2278		2279		2280		2281		2282		2283		2284		2285		2286		2287		2288		2289		2290		2291		2292		2293		2294		2295		2296		2297		2298		2299		2300		2301		2302		2303		2304		2305		2306		2307		2308		2309		2310		2311		2312		2313		2314		2315		2316		2317		2318		2319		2320		2321		2322		2323		2324		2325		2326		2327		2328		2329		2330		2331		2332		2333		2334		2335		2336		2337		2338		2339		2340		2341		2342		2343		2344		2345		2346		2347		2348		2349		2350		2351		2352		2353		2354		2355		2356		2357		2358		2359		2360		2361		2362		2363		2364		2365		2366		2367		2368		2369		2370		2371		2372		2373		2374		2375		2376		2377		2378		2379		2380		2381		2382		2383		2384		2385		2386		2387		2388		2389		2390		2391		2392		2393		2394		2395		2396		2397		2398		2399		2400		2401		2402		2403		2404		2405		2406		2407		2408		2409		2410		2411		2412		2413		2414		2415		2416		2417		2418		2419		2420		2421		2422		2423		2424		2425		2426		2427		2428		2429		2430		2431		2432		2433		2434		2435		2436		2437		2438		2439		2440		2441		2442		2443		2444		2445		2446		2447		2448		2449		2450		2451		2452		2453		2454		2455		2456		2457		2458		2459		2460		2461		2462		2463		2464		2465		2466		2467		2468		2469		2470		2471		2472		2473		2474		2475		2476		2477		2478		2479		2480		2481		2482		2483		2484		2485		2486		2487		2488		2489		2490		2491		2492		2493		2494		2495		2496		2497		2498		2499		2500		2501		2502		2503		2504		2505		2506		2507		2508		2509		2510		2511		2512		2513		2514		2515		2516		2517		2518		2519		2520		2521		2522		2523		2524		2525		2526		2527		2528		2529		2530		2531		2532		2533		2534		2535		2536		2537		2538		2539		2540		2541		2542		2543		2544		2545		2546		2547		2548		2549		2550		2551		2552		2553		2554		2555		2556		2557		2558		2559		2560		2561		2562		2563		2564		2565		2566		2567		2568		2569		2570		2571		2572		2573		2574		2575		2576		2577		2578		2579		2580		2581		2582		2583		2584		2585		2586		2587		2588		2589		2590		2591		2592		2593		2594		2595		2596		2597		2598		2599		2600		2601		2602		2603		2604		2605		2606		2607		2608		2609		2610		2611		2612		2613		2614		2615		2616		2617		2618		2619		2620		2621		2622		2623		2624		2625		2626		2627		2628		2629		2630		2631		2632		2633		2634		2635		2636		2637		2638		2639		2640		2641		2642		2643		2644		2645		2646		2647		2648		2649		2650		2651		2652		2653		2654		2655		2656		2657		2658		2659		2660		2661		2662		2663		2664		2665		2666		2667		2668		2669		2670		2671		2672		2673		2674		2675		2676		2677		2678		2679		2680		2681		2682		2683		2684		2685		2686		2687		2688		2689		2690		2691		2692		2693		2694		2695		2696		2697		2698		2699		2700		2701		2702		2703		2704		2705		2706		2707		2708		2709		2710		2711		2712		2713		2714		2715		2716		2717		2718		2719		2720		2721		2722		2723		2724		2725		2726		2727		2728		2729		2730		2731		2732		2733		2734		2735		2736		2737		2738		2739		2740		2741		2742		2743		2744		2745		2746		2747		2748		2749		2750		2751		2752		2753		2754		2755		2756		2757		2758		2759		2760		2761		2762		2763		2764		2765		2766		2767		2768		2769		2770		2771		2772		2773		2774		2775		2776		2777		2778		2779		2780		2781		2782		2783		2784		2785		2786		2787		2788		2789		2790		2791		2792		2793		2794		2795		2796		2797		2798		2799		2800		2801		2802		2803		2804		2805		2806		2807		2808		2809		2810		2811		2812		2813		2814		2815		2816		2817		2818		2819		2820		2821		2822		2823		2824		2825		2826		2827		2828		2829		2830		2831		2832		2833		2834		2835		2836		2837		2838		2839		2840		2841		2842		2843		2844		2845		2846		2847		2848		2849		2850		2851		2852		2853		2854		2855		2856		2857		2858		2859		2860		2861		2862		2863		2864		2865		2866		2867		2868		2869		2870		2871		2872		2873		2874		2875		2876		2877		2878		2879		2880		2881		2882		2883		2884		2885		2886		2887		2888		2889		2890		2891		2892		2893		2894		2895		2896		2897		2898		2899		2900		2901		2902		2903		2904		2905		2906		2907		2908		2909		2910		2911		2912		2913		2914		2915		2916		2917		2918		2919		2920		2921		2922		2923		2924		2925		2926		2927		2928		2929		2930		2931		2932		2933		2934		2935		2936		2937		2938		2939		2940		2941		2942		2943		2944		2945		2946		2947		2948		2949		2950		2951		2952		2953		2954		2955		2956		2957		2958		2959		2960		2961		2962		2963		2964		2965		2966		2967		2968		2969		2970		2971		2972		2973		2974		2975		2976		2977		2978		2979		2980		2981		2982		2983		2984		2985		2986		2987		2988		2989		2990		2991		2992		2993		2994		2995		2996		2997		2998		2999		3000		3001		3002		3003		3004		3005		3006		3007		3008		3009		3010		3011		3012		3013		3014		3015		3016		3017		3018		3019		3020		3021		3022		3023		3024		3025		3026		3027		3028		3029		3030		3031		3032		3033		3034		3035		3036		3037		3038		3039		3040		3041		3042		3043		3044		3045		3046		3047		3048		3049		3050		3051	
---------	--	-----------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--

[illegible]

TABLE 1		Low		Mid		High		Very High		Extreme		Total		Weighted											
Low	Mid	High	Very High	Extreme	Low	Mid	High	Very High	Extreme	Low	Mid	High	Very High	Extreme	Weighted										
1	15	-21	26	24	22	3	21	23	24	-4	-3.8	-4.4	-1.6	-4.4	3.2	3.1	22	2.6	1.7	3.0	1.1	-1	1	-4.1	3.8
1	17	-18	21	22	2	16	16	2	1.8	-12	-4.6	-1.8	-23	-18	26	25	1.8	24	1.6	3.6	1.1	-1.1	1	-1.1	3.8
1	18	-17	4	15	35	38	43	32	21	11	-3.3	-12	-1.4	-1.3	35	-19	24	2.6	1.6	6.6	-1.2	-1.1	1	-1.2	3.8
1	17	-16	44	-12	2	21	16	48	2	33	-1.6	-1	-1.6	-1	41	2.3	17	1.5	2.3	3.3	1.2	1.1	1	-1.1	-4.8
1	16	-11	44	-11	36	32	37	5	26	1.8	-4	1	-3.7	-3.3	34	4.6	1.3	3.3	2.3	3.6	-1.6	-1.2	1	-1	-1.2
1	14	-11	27	16	12	13	43	37	22	1.1	-1	-1	1	23	34	2	1.8	2.2	3.1	1.1	-1	-1	1	-1.1	1
1	18	-11	36	12	24	2	24	31	17	1.8	1.2	1	-1.8	-1	24	2.7	1.1	24	1.6	2.9	-1.4	1.1	1	-1	-1.4
1	15	12	24	39	22	17	26	26	27	21	2	-4.2	-1.9	1	14	1.6	2.8	1.6	2	3	1.2	-1.1	1	-1.2	-2.2
1	14	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	-2.6
1	12	-12	24	-11	2	27	15	18	38	3	14	1.1	1.4	1.1	36	34	32	14	2.6	3.8	2.7	1.1	1	1	1
1	12	-24	36	-11	24	11	23	24	16	25	-15	-12	-1.8	-1.1	27	1.2	2.1	1.6	1.2	3.1	1.2	1.1	1	-1.2	-1.8
1	11	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	-1.2
1	14	-12	31	-13	12	6.1	3.1	1.6	1.8	-5.1	2	-12	-14.4	-1	23	2	1.9	1.9	1.3	2.6	14	1	1	-1.2	4.6
1	12	-2	24	11	17	15	-1	2	1.9	-11	-23	-4.4	-1.6	-1.3	1.6	2.6	11	1.3	1.3	1.4	-1.3	1.1	1	-1.1	-4.5
1	12	14	31	-13	16	12	23	87	-13	13	-13	1.2	1.3	1.1	19	1.5	1.9	2.5	1.8	2.3	1.1	-1.4	1	-1.2	4.2
1	11	-23	39	-13	26	2	37	28	2.8	-21	-1.2	1.1	-1.2	1.1	1.3	1.6	2	1.4	2	1.3	1.4	1.8	1	-1.1	3.8
1	11	1.6	-13	6.7	8.7	1.9	1.6	1	1.7	35	1.5	1.3	1.3	1.1	1.8	2.5	24	1.7	14	1	2.6	1	1	1	1.5
1	21	14	38	-21	-15	1.5	5.3	-1.8	3.2	-4.8	-1.8	-4.2	-4.1	-4.1	22	1.5	2.3	2.8	2.1	1.1	-1.3	1	-1.2	-1.7	-1.7
1	15	12	37	-15	15	-1	2.1	6	-1.5	1.1	-1.3	-1.1	1	1	1.6	1.2	1.8	2.3	1.8	2.8	1.1	-1.3	1	-1.1	-4.4
1	11	-11	-13	1.6	6.8	2.8	1.9	3	3.1	21	2.6	-1	-1.7	1.9	2.9	2	2.1	3.2	1.3	1	1	-1.2	1	-1.2	-2.7

TABLE 2

		Q223	Q224	Q225	Q226	Q227	Q228	Q229	Q230	Q231	Q232	Q233	Q234	Q235	Q236	Q237	Q238	Q239	Q240	Q241	Q242	Q243	Q244	Q245	Q246	Q247	Q248	Q249	Q250	Q251	Q252	Q253	Q254	Q255	Q256	Q257	Q258	Q259	Q260	Q261	Q262	Q263	Q264	Q265	Q266	Q267	Q268	Q269	Q270	Q271	Q272	Q273	Q274	Q275	Q276	Q277	Q278	Q279	Q280	Q281	Q282	Q283	Q284	Q285	Q286	Q287	Q288	Q289	Q290	Q291	Q292	Q293	Q294	Q295	Q296	Q297	Q298	Q299	Q300	Q301	Q302	Q303	Q304	Q305	Q306	Q307	Q308	Q309	Q310	Q311	Q312	Q313	Q314	Q315	Q316	Q317	Q318	Q319	Q320	Q321	Q322	Q323	Q324	Q325	Q326	Q327	Q328	Q329	Q330	Q331	Q332	Q333	Q334	Q335	Q336	Q337	Q338	Q339	Q340	Q341	Q342	Q343	Q344	Q345	Q346	Q347	Q348	Q349	Q350	Q351	Q352	Q353	Q354	Q355	Q356	Q357	Q358	Q359	Q360	Q361	Q362	Q363	Q364	Q365	Q366	Q367	Q368	Q369	Q370	Q371	Q372	Q373	Q374	Q375	Q376	Q377	Q378	Q379	Q380	Q381	Q382	Q383	Q384	Q385	Q386	Q387	Q388	Q389	Q390	Q391	Q392	Q393	Q394	Q395	Q396	Q397	Q398	Q399	Q400	Q401	Q402	Q403	Q404	Q405	Q406	Q407	Q408	Q409	Q410	Q411	Q412	Q413	Q414	Q415	Q416	Q417	Q418	Q419	Q420	Q421	Q422	Q423	Q424	Q425	Q426	Q427	Q428	Q429	Q430	Q431	Q432	Q433	Q434	Q435	Q436	Q437	Q438	Q439	Q440	Q441	Q442	Q443	Q444	Q445	Q446	Q447	Q448	Q449	Q450	Q451	Q452	Q453	Q454	Q455	Q456	Q457	Q458	Q459	Q460	Q461	Q462	Q463	Q464	Q465	Q466	Q467	Q468	Q469	Q470	Q471	Q472	Q473	Q474	Q475	Q476	Q477	Q478	Q479	Q480	Q481	Q482	Q483	Q484	Q485	Q486	Q487	Q488	Q489	Q490	Q491	Q492	Q493	Q494	Q495	Q496	Q497	Q498	Q499	Q500	Q501	Q502	Q503	Q504	Q505	Q506	Q507	Q508	Q509	Q510	Q511	Q512	Q513	Q514	Q515	Q516	Q517	Q518	Q519	Q520	Q521	Q522	Q523	Q524	Q525	Q526	Q527	Q528	Q529	Q530	Q531	Q532	Q533	Q534	Q535	Q536	Q537	Q538	Q539	Q540	Q541	Q542	Q543	Q544	Q545	Q546	Q547	Q548	Q549	Q550	Q551	Q552	Q553	Q554	Q555	Q556	Q557	Q558	Q559	Q560	Q561	Q562	Q563	Q564	Q565	Q566	Q567	Q568	Q569	Q570	Q571	Q572	Q573	Q574	Q575	Q576	Q577	Q578	Q579	Q580	Q581	Q582	Q583	Q584	Q585	Q586	Q587	Q588	Q589	Q590	Q591	Q592	Q593	Q594	Q595	Q596	Q597	Q598	Q599	Q600	Q601	Q602	Q603	Q604	Q605	Q606	Q607	Q608	Q609	Q610	Q611	Q612	Q613	Q614	Q615	Q616	Q617	Q618	Q619	Q620	Q621	Q622	Q623	Q624	Q625	Q626	Q627	Q628	Q629	Q630	Q631	Q632	Q633	Q634	Q635	Q636	Q637	Q638	Q639	Q640	Q641	Q642	Q643	Q644	Q645	Q646	Q647	Q648	Q649	Q650	Q651	Q652	Q653	Q654	Q655	Q656	Q657	Q658	Q659	Q660	Q661	Q662	Q663	Q664	Q665	Q666	Q667	Q668	Q669	Q670	Q671	Q672	Q673	Q674	Q675	Q676	Q677	Q678	Q679	Q680	Q681	Q682	Q683	Q684	Q685	Q686	Q687	Q688	Q689	Q690	Q691	Q692	Q693	Q694	Q695	Q696	Q697	Q698	Q699	Q700	Q701	Q702	Q703	Q704	Q705	Q706	Q707	Q708	Q709	Q710	Q711	Q712	Q713	Q714	Q715	Q716	Q717	Q718	Q719	Q720	Q721	Q722	Q723	Q724	Q725	Q726	Q727	Q728	Q729	Q730	Q731	Q732	Q733	Q734	Q735	Q736	Q737	Q738	Q739	Q740	Q741	Q742	Q743	Q744	Q745	Q746	Q747	Q748	Q749	Q750	Q751	Q752	Q753	Q754	Q755	Q756	Q757	Q758	Q759	Q760	Q761	Q762	Q763	Q764	Q765	Q766	Q767	Q768	Q769	Q770	Q771	Q772	Q773	Q774	Q775	Q776	Q777	Q778	Q779	Q780	Q781	Q782	Q783	Q784	Q785	Q786	Q787	Q788	Q789	Q790	Q791	Q792	Q793	Q794	Q795	Q796	Q797	Q798	Q799	Q800	Q801	Q802	Q803	Q804	Q805	Q806	Q807	Q808	Q809	Q810	Q811	Q812	Q813	Q814	Q815	Q816	Q817	Q818	Q819	Q820	Q821	Q822	Q823	Q824	Q825	Q826	Q827	Q828	Q829	Q830	Q831	Q832	Q833	Q834	Q835	Q836	Q837	Q838	Q839	Q840	Q841	Q842	Q843	Q844	Q845	Q846	Q847	Q848	Q849	Q850	Q851	Q852	Q853	Q854	Q855	Q856	Q857	Q858	Q859	Q860	Q861	Q862	Q863	Q864	Q865	Q866	Q867	Q868	Q869	Q870	Q871	Q872	Q873	Q874	Q875	Q876	Q877	Q878	Q879	Q880	Q881	Q882	Q883	Q884	Q885	Q886	Q887	Q888	Q889	Q890	Q891	Q892	Q893	Q894	Q895	Q896	Q897	Q898	Q899	Q900	Q901	Q902	Q903	Q904	Q905	Q906	Q907	Q908	Q909	Q910	Q911	Q912	Q913	Q914	Q915	Q916	Q917	Q918	Q919	Q920	Q921	Q922	Q923	Q924	Q925	Q926	Q927	Q928	Q929	Q930	Q931	Q932	Q933	Q934	Q935	Q936	Q937	Q938	Q939	Q940	Q941	Q942	Q943	Q944	Q945	Q946	Q947	Q948	Q949	Q950	Q951	Q952	Q953	Q954	Q955	Q956	Q957	Q958	Q959	Q960	Q961	Q962	Q963	Q964	Q965	Q966	Q967	Q968	Q969	Q970	Q971	Q972	Q973	Q974	Q975	Q976	Q977	Q978	Q979	Q980	Q981	Q982	Q983	Q984	Q985	Q986	Q987	Q988	Q989	Q990	Q991	Q992	Q993	Q994	Q995	Q996	Q997	Q998	Q999	Q1000	Q1001	Q1002	Q1003	Q1004	Q1005	Q1006	Q1007	Q1008	Q1009	Q1010	Q1011	Q1012	Q1013	Q1014	Q1015	Q1016	Q1017	Q1018	Q1019	Q1020	Q1021	Q1022	Q1023	Q1024	Q1025	Q1026	Q1027	Q1028	Q1029	Q1030	Q1031	Q1032	Q1033	Q1034	Q1035	Q1036	Q1037	Q1038	Q1039	Q1040	Q1041	Q1042	Q1043	Q1044	Q1045	Q1046	Q1047	Q1048	Q1049	Q1050	Q1051	Q1052	Q1053	Q1054	Q1055	Q1056	Q1057	Q1058	Q1059	Q1060	Q1061	Q1062	Q1063	Q1064	Q1065	Q1066	Q1067	Q1068	Q1069	Q1070	Q1071	Q1072	Q1073	Q1074	Q1075	Q1076	Q1077	Q1078	Q1079	Q1080	Q1081	Q1082	Q1083	Q1084	Q1085	Q1086	Q1087	Q1088	Q1089	Q1090	Q1091	Q1092	Q1093	Q1094	Q1095	Q1096	Q1097	Q1098	Q1099	Q1100	Q1101	Q1102	Q1103	Q1104	Q1105	Q1106	Q1107	Q1108	Q1109	Q1110	Q1111	Q1112	Q1113	Q1114	Q1115	Q1116	Q1117	Q1118	Q1119	Q1120	Q1121	Q1122	Q1123	Q1124	Q1125	Q1126	Q1127	Q1128	Q1129	Q1130	Q1131	Q1132	Q1133	Q1134	Q1135	Q1136	Q1137	Q1138	Q1139	Q1140	Q1141	Q1142	Q1143	Q1144	Q1145	Q1146	Q1147	Q1148	Q1149	Q1150	Q1151	Q1152	Q1153	Q1154	Q1155	Q1156	Q1157	Q1158	Q1159	Q1160	Q1161	Q1162	Q1163	Q1164	Q1165	Q1166	Q1167	Q1168	Q1169	Q1170	Q1171	Q1172	Q1173	Q1174	Q1175	Q1176	Q1177	Q1178	Q1179	Q1180	Q1181	Q1182	Q1183	Q1184	Q1185	Q1186	Q1187	Q1188	Q1189	Q1190	Q1191	Q1192	Q1193	Q1194	Q1195	Q1196	Q1197	Q1198	Q1199	Q1200	Q1201	Q1202	Q1203	Q1204	Q1205	Q1206	Q1207	Q1208	Q1209	Q1210	Q1211	Q1212	Q1213	Q1214	Q1215	Q1216	Q1217	Q1218	Q1219	Q1220	Q1221	Q1222	Q1223	Q1224	Q1225	Q1226	Q1227	Q1228	Q1229	Q1230	Q1231	Q1232	Q1233	Q1234	Q1235	Q1236	Q1237	Q1238	Q1239	Q1240	Q1241	Q1242	Q1243	Q1244	Q1245	Q1246	Q1247	Q1248	Q1249	Q1250	Q1251	Q1252	Q1253	Q1254	Q1255	Q1256	Q1257	Q1258	Q1259	Q1260	Q1261	Q1262	Q1263	Q1264	Q1265	Q1266	Q1267	Q1268	Q1269	Q1270	Q1271	Q1272	Q1273	Q1274	Q1275	Q1276	Q1277	Q1278	Q1279	Q1280	Q1281	Q1282	Q1283	Q1284	Q1285	Q1286	Q1287	Q1288	Q1289	Q1290	Q1291	Q1292	Q1293	Q1294	Q1295	Q1296	Q1297	Q1298	Q1299	Q1300	Q1301	Q1302	Q1303	Q1304	Q1305	Q1306	Q1307	Q1308	Q1309	Q1310	Q1311	Q1312	Q1313	Q1314	Q1315	Q1316	Q1317	Q1318	Q1319	Q1320	Q1321	Q1322	Q1323	Q1324	Q1325	Q1326	Q1327	Q1328	Q1329	Q1330	Q1331	Q1332	Q1333	Q1334	Q1335	Q1336	Q1337	Q1338	Q1339	Q1340	Q1341	Q1342	Q1343	Q1344	Q1345	Q1346	Q1347	Q1348	Q1349	Q1350	Q1351	Q1352	Q1353	Q1354	Q1355	Q1356	Q1357	Q1358	Q1359	Q1360	Q1361	Q1362	Q1363	Q1364	Q1365	Q1366	Q1367	Q1368	Q1369	Q1370	Q1371	Q1372	Q1373	Q1374	Q1375	Q1376	Q1377	Q1378	Q1379	Q1380	Q1381	Q1382	Q1383	Q1384	Q1385	Q1386	Q1387	Q1388	Q1389	Q1390	Q1391	Q1392	Q1393	Q1394	Q1395	Q1396	Q1397	Q1398	Q1399	Q1400	Q1401	Q1402	Q1403	Q1404	Q1405	Q1406	Q1407	Q1408	Q1409	Q1410	Q1411	Q1412	Q1413	Q1414	Q1415	Q1416	Q1417	Q1418	Q1419	Q1420	Q1421	Q1422	Q1423	Q1424	Q1425	Q1426	Q1427	Q1428	Q1429	Q1430	Q1431	Q1432	Q1433	Q1434	Q1435	Q1436	Q1437	Q1438	Q1439	Q1440	Q1441	Q1442	Q1443	Q1444	Q1445	Q1446	Q1447	Q1448	Q1449	Q1450	Q1451	Q1452	Q1453	Q1454	Q1455	Q1456	Q1457	Q1458	Q1459	Q1460	Q1461	Q1462	Q1463	Q1464	Q1465	Q1466	Q1467	Q1468	Q1469	Q1470	Q1471	Q1472	Q1473	Q1474	Q1475	Q1476	Q1477	Q1478	Q1479	Q1480	Q1481	Q1482	Q1483	Q1484	Q1485	Q1486	Q1487	Q1488	Q1489	Q1490	Q1491	Q1492	Q1493	Q1494	Q1495	Q1496	Q1497	Q1498	Q1499	Q1500	Q1501	Q1502	Q1503	Q1504	Q1505	Q1506	Q1507	Q1508	Q1509	Q1510	Q1511	Q1512	Q1513	Q1514	Q1515	Q1516	Q1517	Q1518	Q1519	Q1520	Q1521	Q1522	Q1523	Q1524	Q15
--	--	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-----

TABLE 2

row	low	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35	36	37	38	39	40	41	42	43	44	45	46	47	48	49	50	51	52	53	54	55	56	57	58	59	60	61	62	63	64	65	66	67	68	69	70	71	72	73	74	75	76	77	78	79	80	81	82	83	84	85	86	87	88	89	90	91	92	93	94	95	96	97	98	99	100	101	102	103	104	105	106	107	108	109	110	111	112	113	114	115	116	117	118	119	120	121	122	123	124	125	126	127	128	129	130	131	132	133	134	135	136	137	138	139	140	141	142	143	144	145	146	147	148	149	150	151	152	153	154	155	156	157	158	159	160	161	162	163	164	165	166	167	168	169	170	171	172	173	174	175	176	177	178	179	180	181	182	183	184	185	186	187	188	189	190	191	192	193	194	195	196	197	198	199	200	201	202	203	204	205	206	207	208	209	210	211	212	213	214	215	216	217	218	219	220	221	222	223	224	225	226	227	228	229	230	231	232	233	234	235	236	237	238	239	240	241	242	243	244	245	246	247	248	249	250	251	252	253	254	255	256	257	258	259	260	261	262	263	264	265	266	267	268	269	270	271	272	273	274	275	276	277	278	279	280	281	282	283	284	285	286	287	288	289	290	291	292	293	294	295	296	297	298	299	300	301	302	303	304	305	306	307	308	309	310	311	312	313	314	315	316	317	318	319	320	321	322	323	324	325	326	327	328	329	330	331	332	333	334	335	336	337	338	339	340	341	342	343	344	345	346	347	348	349	350	351	352	353	354	355	356	357	358	359	360	361	362	363	364	365	366	367	368	369	370	371	372	373	374	375	376	377	378	379	380	381	382	383	384	385	386	387	388	389	390	391	392	393	394	395	396	397	398	399	400	401	402	403	404	405	406	407	408	409	410	411	412	413	414	415	416	417	418	419	420	421	422	423	424	425	426	427	428	429	430	431	432	433	434	435	436	437	438	439	440	441	442	443	444	445	446	447	448	449	450	451	452	453	454	455	456	457	458	459	460	461	462	463	464	465	466	467	468	469	470	471	472	473	474	475	476	477	478	479	480	481	482	483	484	485	486	487	488	489	490	491	492	493	494	495	496	497	498	499	500	501	502	503	504	505	506	507	508	509	510	511	512	513	514	515	516	517	518	519	520	521	522	523	524	525	526	527	528	529	530	531	532	533	534	535	536	537	538	539	540	541	542	543	544	545	546	547	548	549	550	551	552	553	554	555	556	557	558	559	560	561	562	563	564	565	566	567	568	569	570	571	572	573	574	575	576	577	578	579	580	581	582	583	584	585	586	587	588	589	590	591	592	593	594	595	596	597	598	599	600	601	602	603	604	605	606	607	608	609	610	611	612	613	614	615	616	617	618	619	620	621	622	623	624	625	626	627	628	629	630	631	632	633	634	635	636	637	638	639	640	641	642	643	644	645	646	647	648	649	650	651	652	653	654	655	656	657	658	659	660	661	662	663	664	665	666	667	668	669	670	671	672	673	674	675	676	677	678	679	680	681	682	683	684	685	686	687	688	689	690	691	692	693	694	695	696	697	698	699	700	701	702	703	704	705	706	707	708	709	710	711	712	713	714	715	716	717	718	719	720	721	722	723	724	725	726	727	728	729	730	731	732	733	734	735	736	737	738	739	740	741	742	743	744	745	746	747	748	749	750	751	752	753	754	755	756	757	758	759	760	761	762	763	764	765	766	767	768	769	770	771	772	773	774	775	776	777	778	779	780	781	782	783	784	785	786	787	788	789	790	791	792	793	794	795	796	797	798	799	800	801	802	803	804	805	806	807	808	809	810	811	812	813	814	815	816	817	818	819	820	821	822	823	824	825	826	827	828	829	830	831	832	833	834	835	836	837	838	839	840	841	842	843	844	845	846	847	848	849	850	851	852	853	854	855	856	857	858	859	860	861	862	863	864	865	866	867	868	869	870	871	872	873	874	875	876	877	878	879	880	881	882	883	884	885	886	887	888	889	890	891	892	893	894	895	896	897	898	899	900	901	902	903	904	905	906	907	908	909	910	911	912	913	914	915	916	917	918	919	920	921	922	923	924	925	926	927	928	929	930	931	932	933	934	935	936	937	938	939	940	941	942	943	944	945	946	947	948	949	950	951	952	953	954	955	956	957	958	959	960	961	962	963	964	965	966	967	968	969	970	971	972	973	974	975	976	977	978	979	980	981	982	983	984	985	986	987	988	989	990	991	992	993	994	995	996	997	998	999	1000
-----	-----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	------



# TABLE III

>40\_TCC\_13F11\_M13F.fa TIME: Sun Sep 10 11:42:06 2000 trimming  
information: raw\_sequence:582 (high quality:29-320) sequence:97-  
252 [length:156]

TCCGCTCTCATTGAGGGTTCCTGAGGAAGTTGATCTCATCATTCAGGGCATC  
CACCTTGGCCCTCCAGCTCCACCTTGCTCATGTAGGCAGCATCCACATCCT  
TCTTCAGCACCAAACTCATTCTCAGCAGCTGTGCGGCGGTTAATTTCA  
TCTTCG

>04\_TCC\_94G3\_M13F.TXT.fa ,constant: 15, poly A: yes  
AAGCCTTATPCCATCCGGACCGCATCCGCCAGTCGCGAGAGTGCCTGGAGCTGAGCCGCC  
TCCCACCACTCCACTCCTCCAGCCACCCACCAATCACAAGAAGATTCCACCCCTGCC  
TCCCATCCCTGGTCCCAAGACAGTGAGACAGTCTGGAAAGTGATGTCAGAATAGCTTCCA  
ATAAAGCAGCCTCATTTCTGAGGCCTGAGTGAAAAA

>20\_TCC\_60H4\_M13F.TXT.fa ,constant: -1, poly A: no  
CANTATATAACNAATTGGAGCTCAATNGCNCGCCGNCGCCGTGTCTTCTGGGTAGAGGGAT  
GNGAAGGAAGGGACCTTACCCCCGGCTCTTCTCCTGACCTGCCAATAAAATTTATGGT  
CCAAAGNAAAAA

>26\_TCC\_44C1\_M13F.TXT.fa ,constant: -1, poly A: no  
ACTCATTGAACCTTGAGCTCCGANTCCTGATTNCATCNAAGCTCTNNATCTGCTCATCAN  
GAGANCCCATCATCTCTTGAGCAGATGGNGCANCTGCTGNTAAACANCTCTNNAACTCGN  
AGANNNTAAGGCTATCCTTCCGNCCTCCTGCTTGCCTGCAAGGTGAAGAAGTGGTGNNCA  
CNGTCNCAATGGANTCCTCTAGCTCTGTGAGTGGTCTGCTGCNATTATGGAACCTGAGG  
CCAAAGCTGATGTCTTCAAGGGCTAGCTGACCTTTGTGAGGGCTGACCTCTCCTCAGCG  
GCAGCAGGGCAGAGTGCTGAACCCAGGAACCCACAGATCCTCCCCGNTCCTGTCTCCCGG  
TGACAAGGGTCTTGAACGGGGCGTCTCTGACTCCCTGCTCCAGGACGGGTTAAGT

>29\_TCC\_48G1\_M13F.TXT.fa ,constant: -1, poly A: no  
ACTTTGAGAAGGCAGGACTCAATGATGCCCTGGAGATGTACAGATTCTTGGCAGAGCC  
ATGCTCCAGGCTTCCCAAAGTGTTGTTGGCAATTATTCCTAGGCTGAGCCTGCTC  
ATGT

>31\_TCC\_65B9\_M13F.TXT.fa ,constant: -1, poly A: yes  
GACTAGAACCCACCCCTTNCCTTCCAGCCTTTCTGTCTATCTCTCCAGNCCANCCAT  
CCCCTGAGCACATACCATCTCATGCAGGCCCCACCTGCCAATAGTAATAAGCAATGT  
CACTTTGTTAAACATGAAAAA

>47\_TCC\_91B11\_M13F.TXT.fa ,constant: -1, poly A: yes  
CTAGTATACACTCNCATAGNATACGTTGCGAGCTCAATTGCGCGCGGNCGCGGACGACGA  
CCTGCGAGGGTGCTCTTCTGGGTAGAGGGATGGGAAGGAAGGACCTTACCCCCGGCTCT  
TCTCCTGACCTGCCAATAAAATTTATGGTCCAAGGAAAAA

>10\_TCC\_53H11\_T3  
TTTTTTNNATNTTATTTGGGTATTGGTGTNTTTCTTTTTCTTCTTNCCTTCTTAAC  
CAAGACTTGTAGTGTGTAAACCTGCCTCACAAAATACATGGTAATAACTTNTCTTTAAA  
AAAAAAGAGCAGNCTTNACACATTTCTAATNGNANNACTATTTTTGGGCAATGTT  
ATGCACCACTTCAATTTCCCATTTGTACCCCTATCACTTCATTTGATATCCCTTTTNGA  
CCCNCCATCTCCTTCATATATGGGCATGTCCATAGATTGACAAAGAAAGTTTACACTTT  
NGAATAAAGATGCAAGATATGCAAAACATTAATACTGATGCNAAAAAANTANAAAA

>07\_TCC\_57B3\_M13F.TXT ,constant: -1, poly A: yes  
GGTACCGACGGAACCTGCGGAGACTCCTGCCCTGTTGTGTATAGATGCAAGATATTTATAT  
ATATTTTGGGTGCAATATTAAATACAGACACTAAGTTATAGTATATCTGGCAAGCCCAAC  
TGTAATACACCCTCACTCCTGTACTTACCTAAACAGATATAATGGCTGGTTTTTAA  
GAAAAAAAAA

>11\_TCC\_25F2\_M13F.TXT ,constant: -1, poly A: no  
ACCTCGGGAGAGCAAGTTTGAAGAAACACAGCTGATGGCAGAAAACTCAGACTGCTGCA  
ACTTTACAGATGGTGCATTGNGTCAGCATAGGAGTGAGATGGGGAAGGAAAGCACAANTAA  
CAAGAAAAATTCANAGATGNTAAATTAGTGNTGGAGTGTGTGCATGAACAATGCACCTGT

>25\_TCC\_50G5\_M13F.TXT ,constant: 17, poly A: yes  
TAGTGTGGGAAGCATAGTGAACACACTGATTAGGTTATGGTTTAAATGTTACAACAACATATT  
TTTTAAGAAAAACATGTTTTAGAAATTGGTTTTCAAGTGACATGTGTGAAAAACAATATTGC  
ATACTACCATAGTGAGCCATGATTTTCTAAAAAAA

>26\_TCC\_50G6\_M13F.TXT ,constant: 17, poly A: yes  
TAGTGTGGGAAGCATAGTGAACACACTGATTAGGTTATGGTTTAAATGTTACAACAACATATT  
TTTTAAGAAAAACAAAGTTTTAGAAATTGGTTTCAAGTGACATGTGTGAAAAACAATATTGT  
ATACTACCATAGTGAGCCATGATTTTCTAAAAAAA

>26\_TCC\_75E3\_M13F\_B04\_032.ab1.TXT ,constant: 16, poly A: yes  
AAAGAGGGCGGCGAGGGGCTGGAGATCCTCCTGCAGACCACGCCCGTCTGCCCTGTGGCG  
CCGTCTCCAGGGGCTGCTTCTCCTGGAAATTGACGAGGGGTGCTTGGGCAGAGCTGGC  
TCTGAGCGCCCTCCATCCAAAGGCCAGGTCTCCGTAGCTCCTGTGGCCCAACCTGGG  
CCGTGGGCTGCAATCAGGAATATTTCCAAAGAGTGATAGTCTTTTGTCTTTTGGCAAA  
ACTCTACTTAATCCAAATGGGTTTTTCTCTGTACAGTAGATTTTCCAAATGTAATAAACTT  
TAATATAAAGTAAAAAAA

>30\_TCC\_76B3\_M13F\_F04\_042.ab1.TXT ,constant: 16, poly A: yes  
AAAGTCATCCTCGGTCTACAGAGCGTGCATCTGATCCTAAATAAGCTTCACTCTCCG  
GGCTGTGCCCTTGGGGTGGAAAGGGGAGGATCTGCAGCTGCTTTTGCATTCTCTCC  
TAAATTTCAATGTGTGATTCTTTCTTCCCTCCCAATAGGTGATCTTAATTACTTTCAGAAAT  
ATTTTCAAAATAGATATATTTTAAATCCTTAAAAAAA

>38\_TCC\_56E11\_M13F.TXT ,constant: -1, poly A: yes  
CTCTCCAGTTTGCACCTGTCCCCACCTCCACTCAGCTGTCTGCAGCAAACTCCACC  
CTCCACCTTCCATTTTCCCCCACTACTGCAGCACCTCCAGGCTGTTGCTATAGAGCCTA  
CCTGATGTCAATAAACACAGCTGAAGCAAAAAAAA

>46\_TCC\_78B11\_M13F\_F06\_058.ab1.TXT ,constant: 16, poly A: yes  
AGGAAGGTTGNGNGCTGGAGCACTGAACCTACCTCATCTCCTGGTGGGTGTGGCTACC  
CTCCGCAACCAATTCATGTGATTAAAGAACGCTAAATCAAAAAAAA

>53\_TCC\_79G2\_M13F\_E07\_054.ab1.TXT ,constant: 16, poly A: no  
TGTCCGCTTTCACCCATCCCCAAGCCTACTAGAGCAAGAAACCAGTTGTAATATAAAATG  
CACTGCCCTACTGTTGGTATGACTACCGTTACCTACTGTTGTCTATTGTTATTACAGCTAT  
GGCCACTATTATTAAAGAGCTGTGTAACATCAAAAAA

>82\_TCC\_89G3\_M13F\_B11\_092.ab1.TXT ,constant: 16, poly A: yes  
CAGGAGACCATCCCGCTCACCAAGCCCTGCACCCCAAGACCAAGCAAGGGCCAAAGCC  
AAGAAAGGGAAGGAAAGGACTAGACGCCAAGCCTGGATGCCAAGAGAGCCCTGGTGTCA  
CATGGGCGCTGGGCCACGCCCTCCCTCTCCAGGCCGAGATGTGACCCACCAGTGCCTT  
CTGTCTGCTCGTTAGCTTTAATCAATCATGCCCTGCCTTGTCCCTCTCACTCCCGAGCCC  
CACCCCTAAGTGCCCAAGAGTGGGGAGGGACAAAGGATCTGGGAAGCTTTGAGCCTCCCC  
AAAGCAATGTGAGTCCAGAGCCCGCTTTTGTCTTCCCAACAATTCCATTACTAAGAAA  
CACATCAATAAACTGACTTTTCCCCCAAAAAAAA

>35\_TCC\_21D6\_M13F\_C05\_037.ab1.fa TIME: Wed Aug 9 12:48:31 2000  
trimming information: raw sequence:889 (high quality:34-340)  
sequence:95-456 [length:362]  
CTTTGACGTGGAGAGGAACTCCTGCRATAACTTCATCTATGGAGGCTGCC  
GGGGCAATAAGAACAGCTACCGCTCTGAGGAGGCCTGCATGCTCCGCTGC  
TTCCGCCAGCAGGAGAATCCTCCCTGCCCTTGGCTCAAAGGTGGTGCT  
TCTGGCGGGGCTGTTCGTGATGGTGTGATCCTCTTCTGGGAGCCTCCA  
TGGTCTACCTGATCCGGGTGGCAGGAGGAACCAGGAGCGTGCCCTGCGC  
ACCGTCTGGAGCTCCGNAGATGACAAGGAGCAGCTGGTGAAGAACACATA  
TGTCCTGTGACCGCCCTGTCGCCAAGAGGACTGGNGAAAGGGAGGGGAGA  
CTATGTGTGAGC

>46\_TCC\_27H5\_M13F\_F06\_058.ab1.fa TIME: Wed Aug 9 12:48:35 2000  
trimming information: raw sequence:892 (high quality:169-406)  
sequence:170-287 [length:118]  
AAAAAGAGTAAACACTTTCAGTTTCTCCCTTTAGCCCCATAAAACAACA  
TCTTACAGTCTGGATCTGGATCTACCTATACAGTCTACATTAGCTTCTA  
AAATATTTGTCAGGAGGG

## TABLE IV

>31\_TCC\_10E8\_M13F.fa TIME: Sun Sep 10 11:42:01 2000 trimming  
information: raw\_sequence:549 (high quality:25-313) sequence:98-  
313 [length:216]  
CCCCAAATGGAATGTTGCCCCCTTAAACACCATTTCCTCCAGGACCACC  
TTGGTTTCTAGGCACCTGTGTTCTTGGCAGGGCTGTCTTAGTAAAAAGG  
GTAGTTGTGGAGCTACAGTCTGAAGAACATAGCTTGGGCTCAAGTTCAAA  
TGAGCCATCTCTTTTCTTGGCTTTTCTTGAAGTGAGATGTTAT  
TTGTGGCATGTGAACCT

>09\_TCC\_10I11\_M13F.TXT.fa ,constant: 16, poly A: yes  
ACAAAGACTGCTGATACTATCTGTGATTGATAGGAAATTTTTTCTTGATTCTCTGT  
GAGAAATGTAATGCTGACTTTTATAAGCCTGGACTTCTACTTTATTAATAAATCAATG  
TTTGCAATGGTAAAAAAA

>11\_TCC\_10I11\_M13F.TXT.fa ,constant: 15, poly A: yes  
GCAATAAAGCTGTCCATTCAATCCAAATAGTGGTTTTAAGNGTAGCCACTGATATTC  
TTTCATGNTAGAAATCTTCTTCTGTTATTATCAAGAAATGTTTTAATCATGCTAATA  
AACTTTTTTGAGATGAAAAAAA

>15\_TCC\_57C3\_M13F.TXT.fa ,constant: -1, poly A: no  
GGNACCACGTACCTGTGTAATGNTCNCNNGNATGNCNCAGGCCATGCTGTTGCTGATN  
TANTACTNTGAAATANGGATATCATGATGGGAATGCATGTCATGAGGTCAGANTCGTT  
CTACTGTCTNATAANCTGTNTACTNGCGTTGANAANAANGATGTCAAAGNCCCCCGTAA  
AAANGTA

>44\_TCC\_70E8\_M13F.TXT.fa ,constant: 15, poly A: yes  
GTCCCAGTCTTCACAGGTGTCTCTCTCTTTTACTCAGGAGGACTTTCCAGGAAAACC  
ATGCCACTAGCAAAAAAAA

>03\_TCC\_57E11\_T7.TXT.fa ,constant: 16, poly A: yes  
TCAGTGTCTTCAGGCCAACCTGGTGGAATGTTGTTCTCTGAAGATTAAGATTTTAGGAT  
GGCAATCATGTCTTGATGCTCTGATTTGTTCTAGTATCAATAAAGTGTATACTTGCTTTG  
AATTCATGTTAGCAATAAATGATGTAAAAAAA

>08\_TCC\_70E7\_M13F\_H01\_015.ab1.TXT ,constant: -1, poly A: no  
GGATCGAGGACCTGCTTCCAGANGCGNCCNNGAGGNCNCCTTGTNNNGNCNNGNANAC  
NNACCANTTNANTNNAGCCTTTNTGNAATAAATATACACAGGCCACCCATGCCNTGAG  
CACACTAACACNTGATGCAGGCCCCACCTTGCCAATAGTAATAAGCANTGGGACGTTT  
TTTA

>13\_TCC\_71E4\_M13F\_E02\_018.ab1.TXT ,constant: -1, poly A: no  
GGGCCAAAGCCGNGCATCCAANCCCCANGCAAGGNACAAANGANCNNGGAGAGANNACC  
CAAGCANNNNCAACCATCAAATGGAGGGCANGCCCGGGG

>15\_TCC\_71H8\_M13F\_G02\_019.ab1.TXT ,constant: -1, poly A: no  
GGGCCAAAGCCGNGCATCCAANCCCCANGCAAGGNACAAANGANCNNGGAGAGANNACC  
CCANGCCTNTATTAACCATCAANTGGGANGGCAAGCCCGGGGCAATNTATTGATT

>21\_TCC\_43E2\_M13F.TXT ,constant: -1, poly A: no  
AGGACCCCTGAANACNACACAGATCTGTNGAAACAANGGNACNTAGCGTCCCNAAAGTG  
CCNGGTTNNNGTANNCNNAGNGNGGACCNGGNCNCAATNT

[illegible]

2

123

```

24 TCC 12F3_M13F_H03_031.ab1.fa TIMB: Wed Aug 9 12:48:28 2000
trimming information: raw sequence:842 (high quality:82-340)
sequence:98-476 [length:379]
CATGTAATAGCTCTCTGCTTTATGACCTTTAGGATTAACTTGTAAAAACA
TATCCTCGAACTAAGATATGCAAAATACATCTTTCAAGTTATGGAAATGT
GTTTCTGGGCATATAGGACTCTGGGGCTCGTGTGTGTAGTGAGAGTGTGTA
TCACATCTATTAACTGGAATTTAATTTACATTCATAAAGCTATATTTC
CCATCTTGGCAAACTATTTTATGTCCTCACTGCTGTTTCTCTTCGGNATAT
CTTTGGNNTTGAAACCAACATCTTAAATGATGNNATTTTATCTTTTAA
CTTAAAAATTATTAAACAGCTATATGGACCTTATAAAATGATTTCTT
ATTTATTATTGACATTACTACTAAAAGG

```

```
>26_TCC_13H10_M13F_B04_032.ab1.fa  TIME: Wed Aug  9 12:48:29 2000
trimming information: raw_sequence:874 (high quality:67-356)
sequence:99-261 [length:163]
CTAACCCACGATTCTGAGCCCTGAGTATGCCTGGACATTGACTAAACAT
GACCATTGCTTGGGATGTCCTAGCTGTGCTGGGGATAGCTGGAGCACTTA
CTAGGTGGCTGGTGAAATGACACCTACGAAGGAATGAGTGCTATAGAGA
CGACAGAGGAGTG
```

93

>29\_TCC\_17A5\_M13F\_E04\_034.ab1.fa TIME: Wed Aug 9 12:48:30 2000  
trimming information: raw sequence:861 (high quality:83-477)  
sequence:99-187 [length:89]  
CTTCAAAAAGTGTTATTGTCAAACATACCTAACTTTCTTGCAATAAATGCA  
AAAGAACTGGAACCTTGACAATTATAAATAGTAATAGTG

>54\_TCC\_30E5\_M13F\_F07\_062.ab1.fa TIME: Wed Aug 9 12:48:37 2000  
trimming information: raw sequence:836 (high quality:65-394)  
sequence:90-235 [length:146]  
CAATTTGTTATAGTATAGTATCAAATTTCTATATAGATTTTATACCTCAG  
TGGGGAAAAATAACTGATTCCAATGCATTTCATTTTGTTTTTCATCTGTGA  
TAGTCATGGATGCTTTTATTTTCTTGGGGTGCTGAAATTGAGCTG

>59\_TCC\_34D5\_M13F\_C08\_065.ab1.fa TIME: Wed Aug 9 12:48:39 2000  
trimming information: raw sequence:875 (high quality:63-434)  
sequence:96-244 [length:149]  
CCTGCCAAAACTCTACCACAGGATAACATTACAAGCAAAAAATTTACATG  
TTCCAAAGCTTACCACACTCAAGAAGTTACTAAGAAGCTCTTGCAGAATAA  
AAGTCACCATTTTAGAAATGCAAAACCCACTTCCAACCTTTGCACAGTCC

>72\_TCC\_37E11\_M13F\_H09\_079.ab1.fa TIME: Wed Aug 9 12:48:43 2000  
trimming information: raw sequence:899 (high quality:35-432)  
sequence:97-444 [length:348]  
CATTTTTAGTGACATTTTAAAAGCAGTCAGATTCTATAAATGGCAAGTAA  
GCCTGAAGTGAGGATACTGCAATTTTCGGAGAAAAGAACAGCAGCTCTTT  
AAGTGTGTTGCATTTTCTATTGGGGGGCAGGGAACTGTCAATTCATTTTGC  
ACAATTTCTGAACTGATGTGAGCAGCCCGAGTGGCTCCTGAATTTAAGTCT  
GGGACGACATCTTTATTTTACATGAATCTTTAAACAATCTGTGAGCA  
AAGTTTGTAGCTGCTGGATTATTGTCTGTCTTTATAGCAAGTCCAGTAA  
ACCACAAGTAGTGGCAAAGCTTATCCAATTTTATGCTTGNAGCAGTCAG

Table 5 : Subset of 22 genes identified as potential TCC markers

Gene ID	GENE DESCRIPTION	2ndary Gene Description	Accession Number	A
TCC-75E3	Sequence 202 from Patent WO9947569 ; nt_non_genomic(identifier):contig_TCC_75E3_RF.fa	H.sapiens syndecan-1 gene (exons 2-5)	gi 10042244 emb A X017423.1 AX017423	x
TCC-71E4	Sequence 102 from Patent WO9953040 ; nt_non_genomic(identifier):contig_TCC_71E4_RF.fa	Homo sapiens mRNA for hepatocyte growth factor activator inhibitor type 2, complete cds	gi 10041170 emb A X014903.1 AX014903	x
TCC-94G3	Human mRNA fragment for mesothelial type II kerat ; nt_non_genomic(identifier):contig_TCC_94G3_RF.fa		gi 34067 emb X03212.1 HHSKER7R	x
TCC-70E7	none:17_TCC_70E7_1_M13F.fa none:17_TCC_70E7_1_M13R.fa			x
TCC-21G7	Homo sapiens clone PP722 unknown mRNA ; CONTIG_nt_non_genomic(identifier):contig_TCC_21G7_RF.fa		gi 10441985 gb AF212.1 HHSKER7R	x
TCC-93G5	Homo sapiens cystatin B (CSTB) gene, promoter reg ; nt_non_genomic(identifier):contig_TCC_93G5_RF.fa		gi 7263011 gb AF208234.1 AF208234	x
TCC-36B5	Sequence 5 from Patent WO9954447 ; nt_non_genomic(identifier):contig_TCC_36B5_RF.fa	Homo sapiens hypothetical protein (LOC51323), mRNA	gi 10040568 emb A X014141.1 AX014141	
TCC-54C11	Homo sapiens actin, gamma 1 (ACTG1) mRNA ; nt_non_genomic(identifier):contig_TCC_54C11_RF.fa		gi 4501886 ref NM_001614.1	
TCC-34A5	Homo sapiens S100 calcium-binding protein P (S100P ; nt_non_genomic(identifier):contig_TCC_34A5_RF.fa		gi 5174662 ref NM_005980.1	x
TCC-70E8	none:contig_TCC_70E8_RF.fa			x
TCC-78B11	Sequence 56 from Patent WO9954353 ; nt_non_genomic(identifier):contig_TCC_78B11_RF.fa	Human growth factor-inducible 2A9 gene, complete cds		
TCC-101E11	Homo sapiens CGI-81 protein (LOC51108), mRNA ; nt_non_genomic(identifier):contig_TCC_101E11_RF.fa		gi 7705788 ref NM_016025.1	x
TCC-102C5	MR1-CT0058-021199-001-c10 CT0058 Homo sapiens cDNA ; est(identifier):contig_TCC_102C5_RF.fa		gi 6873340 gb AW374686.1 AW374686	
TCC-58A3	Homo sapiens keratin 17 (KRT17) mRNA ; nt_non_genomic(identifier):contig_TCC_58A3_RF.fa		gi 303378 emb Z19574.1 HSCYCTOK17	
TCC-57B3	Homo sapiens solute carrier family 2 (facilitated ; nt_non_genomic(identifier):contig_TCC_57B3_RF.fa		gi 5730050 ref NM_006516.1	x
TCC-42G5	Homo sapiens caspase 4, apoptosis-related cystein ; nt_non_genomic(identifier):contig_TCC_42G5_RF.fa		gi 4502576 ref NM_001225.1	
TCC-99G12	Homo sapiens keratin 8 (KRT8) mRNA ; nt_non_genomic(identifier):contig_TCC_99G12_RF.fa		gi 4504918 ref NM_002273.1	
TCC-92D7	Homo sapiens hypothetical protein PRO2987 (PRO298 ; nt_non_genomic(identifier):contig_TCC_92D7_RF.fa		gi 8924228 ref NM_016336.1	
TCC-89G3	Sequence 82 from Patent WO9951727 ; nt_non_genomic(identifier):contig_TCC_89G3_RF.fa	Homo sapiens midkine (neurtie growth-promoting factor 2) (MDK) mRNA	gi 10041391 emb A X015411.1 AX015411	x
TCC-56E11	Homo sapiens Opa-interacting protein OIP3 mRNA, p ; nt_non_genomic(identifier):contig_TCC_56E11_RF.fa		gi 2815605 gb AF205439.1 AF205439	x
TCC-25F2	Sequence 89 from Patent WO9953040 ; nt_non_genomic(identifier):contig_TCC_25F2_RF.fa	Homo sapiens fatty acid binding protein 5 (psoriasis-associated) (FABP5), mRNA	gi 10041157 emb A X014890.1 AX014890	x
TCC-44C1	Homo sapiens S100 calcium-binding protein A13 (S10 ; nt_non_genomic(identifier):contig_TCC_44C1_RF.fa		gi 5174658 ref NM_005979.1	x

## Notes to Table 5

- 1) In column A, "x" indicates that the sequence also appears in Table 1 or 2.
- 2) Table 5 includes known genes whose function in bladder cancer was

heretofore unknown and which were now found to upregulated in bladder cancer (identified by Accession Number) and also includes sequences of novel genes which have no identity to known proteins or genes in the gene databases



Table 6 Polynucleotides corresponding to the Genes described in Table 5.

```

>17_TCC_70E7_1_M13F.fa
GGTAGACGTACCTGCCTCCCAGACTTGACCAGGTGGATCTCCTGTTTTAC
TCACGAGGACTTTCCCGAGAAAACCATGCCACTAGCAAAATATATAAAC
AAAGGA
>17_TCC_70E7_1_M13R.fa
TTTTTTTTTTTTTTTTTGGCTAGAGGCATGGATATCCTGGGAAAGCTCTCC
TGAGTAAAGACGAGAGACACCTGGTGAAGACTGGAACGCATGTACGTCT
ACC
>contig_TCC_101E11_RF.fa
GGTCGACGTACCTGCGCAATAAAGCTGTCCATTCAATCCAAATACTGGT
TTTAAGGTATAGCCACTGATATTCTTTCATGTTTAGAAATCTTCTGTGT
ATTATTCAAGAAATGTTTTAATCATGCTAATAAATCTTTTTGGGAGATG
AAAAAAAAAAAAAAAAAAAA
>contig_TCC_102C5_RF.fa
GCTGGTTGGGGGAATTGGAGGCTTCTAGGAGGTGGCACGGTGCACGCCAA
GATGGCTGTGTCCACAGAGGAGCTGGAGGCCACGGTTTCAGGAAGCTCCTGG
GGAGACTGAAGAGCCACCAAGTTTTCCAGTCCACATGGGACACTGTTGCC
TTCATTGTTTTCTCACCCTCATGGGCACCGTGTCTGCTCCTGCTGCTGCT
GGTCTGCGCCCACTGCTGCTGCTGCGAGCTCCCGCGGGCCCGCAGGGGAAA
GCCCCAGGAAGGAAGACCCAGGGAGCTGGATAACTTGGCCCTGGAAACCC
TGACCCTGTGCTCCTGCCCCGGTGGCAGTAACAAGCCTTCTGCTGCCCC
AGAAAAAAAAAAAAAAAAAAAA
>contig_TCC_21G7_RF.fa
CTAAATCTAGGTATTCTGGCTGAGTGTATCTGGTGCGCCAGCTAAAAAT
AAACCTCATTGAATCCAGCCCCAACCCAGAGAAACATCCAGAAGAGCCT
TGAATTAGTGTATCCAAACCCAGGGGGAAGGCGACATTCTCACCCCCAG
CACCCCTTCACTCACCCTCACTCCTACTCTCTCGGTCTATAATCACTG
CTCTCTCTCCCCAACCACTATTGAACAGGAGCCCTTGTCAACAGGT
CCAAGCAATCCCTAAGGTATCACAAACAATGGTGGATGCAATTTAGCT
TACTCAGTAACCCAGGCTCACATCCCTAATTCAGACTCTACCAGCTC
TCAGGTGCCCTCCCAAGGGCTGCCTGCATGAAGATGCCTTGGCAAGTAGC
CCCTTTCACAACTCACAGGAATTAACCCCTTGGTGTGGAGGGGCTCACT
TTAAGCAATCCAGTAGTAAACATTGGATAAAATCTAAGGCTTTCTTTAA
TTTTTTTTTCTCTCTCGTAAAGGATTCAAAGCAGGCACAGTGGTG
>contig_TCC_25F2_RF.fa
CCCTGGGAGAGAAGTTTGAAGAAACCAAGCTGATGGCAGAAAACTCAG
ACTGTCTGCAACTTTACAGATGGTGCAATTGGTTCAGCATCAGGAGTGGGA
TGGGAAGGAAAGCACAATAACAAGAAATTTAAAGATGGGAAATTAGTGG
TGGAGTGTGTCATGAACAATGTCACCTG
>contig_TCC_34A5_RF.fa
CATGACAGGCTCAGCTAGGGGAATAATTGCCAACAAACACTTTTGGGA
AGCCTGGGACCATGGCTCTGCCAGGAATCTGTGACATCTCCAGGGCATCA
TTTGAGTCTGCTCTCTCAAG
>contig_TCC_36B5_RF.fa
CTCTTCTATGCTAATATGCTCTGGGCTGGAGAAATGAAATCCTCAAGCC
ATCAGGATTTGCTATTAAAGTGGCTTGACAACCTGGGCCACCAAGAACTT
GAATCTCACTTTTAGGATTTGAGCTGTTTGGAAACACATTTGCTGCACCTT
TGGAAAGTCAAAATCAAGTGCCAGTGGCGCCCTTCCATAGAGAATTTGC
CCAGCTTTGCTTTAAAGATGTCTGTTTTTATATACACATAATCAATA
GGTCCATCTGCTCTCAAGGCCTTGGTCTGGTGGGATTCCTTCAACCAAT

```

TACTTTAATTAATAATGGCTGCAACTGTAAGAACCCTTGTCTGATATATT  
 TGCAACTATGCTCCCAATTACAAATG  
 >contig\_TCC\_42G5\_RF.fa  
 CCTTCGGAATACTCTCCTCCAGGTGGCAGCACCAGAATATTTCTGGAAG  
 CATGTGATGAGTTGTGTGATGAAGATAGAGCCCATTTGCTGTCTCTCCA  
 GGACACGTTGTGTGGCGTTGAAGAGCAGAAAGCAATGAAGTCTTCTCCA  
 CGTGGGTCTTGTAAACAGCATCTTCTCCAGGTTCTCAGATGACTGTGAA  
 GAGGCCACTTCCAAGGATGCTGGAGAGTCTTGACCCACAGTTCCTCAAG  
 GTTTGCACCTCTGCAGGCTGGACAATGATGACCTTGGGTTTGTCTCTCA  
 GACTGAGGCGAGTTGGGTTGTGAATATCTGGAAGATGGTGTCTATAAGC  
 AGCACATCTGGTTTTTCTCATCATGCACAGTTCGGCAGATTCCCTCCAG  
 GATGCCATGAGACATGGG

>contig\_TCC\_44C1\_RF.fa  
 CTCATTGAACTTGAGCTCCGAGTCTCTGATTACATCCAAGCTCTTCATCT  
 TCTCATCAAGAGAGCCACATCTTGTAGCAGATGGGGCAACTGCTGGGTG  
 ACCAGCTCTTTGAACTCGTTGAGCTGAGGCTATCCTTCGGCCCTCTGT  
 CCTTGCAAAGGTGAAGAAGGTGGTGACCCAGGTCTCAATGGACTCCTCTA  
 GCTCTGTGAGTGGTTCTGCTGCCATTAGGACCTGAGGCCAAAGCTGATG  
 TCCTCAAGGGGCTAGCTGACCTTTGTGAGGGCTGACCTCTCTCAGCGGC  
 AGCAGGGCAGAGTGTGAACCCAGGACCCACAGATCTCTCCCGCTCCTG  
 TCTCCCGGTGACAAGGCTCCTGGAACGGGGCTCTCTGACTCCCTGCTCC  
 AGGACGGGTTTATG

>contig\_TCC\_54C11\_RF.fa  
 TTTTTTTTTTTTTTTTGGTTACGGCAGCACTTTTATTTTCTTACACA  
 ATGAGCTGTTGCTGGGGCTTAATGTTCTCACATAACAGTAGAAAAACAAA  
 ATTTGTTGTATCTCTTCAAGAATCGAGAATTGCGTACAAAAA  
 AAAAAA

>contig\_TCC\_56E11\_RF.fa  
 CTCTCCAGTTTGACCTGTCCCCACCTCCACTCAGCTGTCTGCGAGCAA  
 ACACTCCACCTCCACCTTCCATTTCCCCCACTACTGCAGCACCTCCAG  
 GCCTGTTGCTATAGAGCTACCTGTATGTCAATAACAACAGCTGAAGCA  
 AAAAAAAAAAAAAA

>contig\_TCC\_57B3\_RF.fa  
 GGTCAGCAGGACCTGCGGAGACTCCTGCCCTGTTGTATAGATGCAAGA  
 TATTATATATATTTTTGGTTGTCAATATTAATAACAGACACTAAGTTAT  
 AGTATATCTGGAACAAGCCAACTTGAATAACACCACTCACTCCTGTTAC  
 TTACCTAACAAGATATAAATGGCTGGTTTTTAGAAAAA  
 A

>contig\_TCC\_58A3\_RF.fa  
 GGCTGGAGCAGGAGATTGCCACCTACGCCGCTGCTGGAGGGAGAGGAT  
 GCCCACTGTACTCAGTACAAGAAAGAACCGGTGACCAACCGTCAAGTGG  
 TACCATTGTGAAGAGGTCCAGGATGGCAAGTCACTCTCTCCCGCAGC  
 AGGTCCACAGACACCCCGCTGAGGACTCAGTACCCCGGCGGCCACCC  
 AGGAGGCAGGGAGGAGCGGCCCATCTGCCCAACAGTCTCCGGCTCTC  
 CAGCTCAGCCCTGCTTCACTCCCTTCCCATGCTTCTTCTGCTGATG  
 ACAATAAAGCTGTTGACTCAGCTAAAAA

>contig\_TCC\_70E8\_RF.fa  
 TTTTTTTTTTTTTTTTGTAGTGGCATGGTTTTCTGGGAAAGTCTCTCC  
 TGAGTAAAGAGGAGAGACCTGGTGAAGACTGGGAGCGAGGTAGTCT

ACC

>contig\_TCC\_71E4\_RF.fa

CTCCAGCGATATGTTCAACTATGAAGAATACTGCACCGCCAACGCGAGTCA  
CTGGGCGCTTGCCTGCATCCTTCCCACGCTGGTACTTTGACGCTGGAGGAGG  
AACTCCTGCAATAACTTTCATCTATGGAGGCTGCCGGGGCAATAAGAACAG  
CTACCGCTCTGAGGAGGCGTGCATGCTCCGCTGCTTCCGCCAGCAGGAGA  
ATCCTCCCTTGCCTTGGCTCAAGGTTGGTGGTCTGGCGGGGCTGTTCT  
GTGATGTTGATGCTCTTCTTCCCTGGGAGCCTCCATGGTCTACCTGATCCG  
GGTGGCAGGAGGAACAGGAGCGTGCCTGCGCACCGCTCTGGAGCTCCG  
GAGATGACAAGGAGCAGCTGGTGAAGAACACATATGCTCTGTGACCGCCC  
TGTGCGCAAGGAGCTGGGAAGGGAGGAGACTATGTGTGAGCTTTTTT  
TAAATAGAGGGATTGACTCGGATTTGAGTGATCATTAGGGCTGAGGCTG  
TTTCTCTGGGAGGTAGGACGGCTGCTTCTGGTCTGGCAGGGATGGGTTT  
GCTTTGGAAATCCTCTAGGAGGCTCCTCCTCGCATGGCTGAGCTCTGGC  
AGCAGCCCCAGTTGTTTCTCGCTGATCGATTCTTTTCTCCAGGTAGA  
GTTTCTTTGCTTATGTTGAATCCATTGCTCTTTTCTCATCACAAG  
TGATGTTGGAATCGTTTCTTTTGTGTTCTGATTTATGGTTTTTTTAAGT  
ATAAACAAAAGTTTTTTATTAGCATTCTGAAAGAGGAAGATAAAATGTA  
CAAGTTTAATAAAAAGGGCCCTCCCTTTAGAATAAAATTCAGCATGTG  
CTTTCAAAAAAAAAAAAAAAAAA

>contig\_TCC\_75E3\_RF.fa

AAAGAGGGCGGCGAGGGCTGGAGATCCTCTGCAGACCACGCCCGCTCCT  
GCCTCTGGCGCGCTCTCCAGGGGCTGCTTCTCTCGAAATATGACGAGGG  
GTGCTCTGGCGAGACTGGCTCTGAGCGCTCCATCCAAGGCAGGCTTCT  
CGTTAGCTCCTGTGGCCCCACCTGGGCGCTGGGCTGGAATCAGGAATA  
TTTTCCAAAGAGTGATAGTCTTTTGTCTTTGGCAAACCTCTACTTTAATCC  
AATGGGTTTTTCTCTGTACAGTAGATTTTCCAATGTAATAACTTTAAT  
ATAAAGTAAAAAAAAAAAAAAAAA

>contig\_TCC\_78B11\_RF.fa

GGACCGGAACAAGGACGAGGTGAACCTCCAGGAGTATGTCACCTTCC  
TGGGGCGCTTGGCTTTGATCTACAATGAAGCCCTCAAGGGCTGAAAATAA  
ATAGGGAAGATGGAGACACCTCTGGGGGCTCTCTCTGAGTCARATCCAG  
TGGTGGGTAATTGTACAATAAATTTTTTTTGGTCAATTTAAAAAAAAAA  
AAAAAA

>contig\_TCC\_89G3\_RF.fa

CAGGAGACCATCCGCGTCACCAAGCCCTGCACCCCCAAGACCAAAGCAAA  
GGCCAAAGCCAGAAGAGGAAGGGAAGGACTAGACGCCAAGCCTGGATG  
CCAAGGAGCCCCCTGGTGTACATGGGCGCTGGCCACGCCCTCCCTCTCC  
CAGGCCCGAGATGTACCCACCAAGTGCCTTCTGTCTGCTCGTTAGCTTTA  
ATCAATCATGCCCTGCCCTTGTCTCTCACTCCCCAGCCCCACCCCTAA  
TGCCCAAAGTGGGAGGGACAAGGGATTCTGGGAAGCTTGAGCCTCCCC  
AAAGCAATGTGAGTCCAGAGCCCGCTTTTGTCTTCTCCCAATTTCCAT  
TACTAAGAAACACATCAATAAAGTACTTTTCCCCCAAAAAAAAAAA  
AAAAA

>contig\_TCC\_92D7\_RF.fa

TTTTTTTTTTTTTTTGAAGACAACTTTAGAAACTGATGTTTATTTTCCA  
TCAACATTTTTTCCATGCTGCTTAAGAGCCTATGCAAGAACAGCTTAAGA  
CCAGTCAGTGGTTGAAGTC

>contig\_TCC\_93G5\_RF.fa

GACTACCAAGACCAACAAAGCCAAGCATGATGAGCTGACCTATTTCTGATC  
CTGACTTTGGACAAGGCCCTTCAGCCAGAAGACTGACAAAGTCATCTCTCC  
GTCTACCAGAGCGTGCACTTGATCCTAAAATAAGCTTTCATCTCCGGGC

TGTGCCCCCTGGGGTGAAGGGGAGGATTCTGCAGCTGCTTTTGCATTT  
 CTCTTCCTAAATTTCATTTGTGTGATTTCCTTCCTTCCCAATAGGTGATC  
 TTAATTACTTTTCAAGATATTTTCAAAATAGATATATTTTAAATCCTTA  
 CAAAAAAAAAAAAAAAAA  
 >contig\_TCC\_94G3\_RF.fa  
 AAGGCTTATTCCATCCGACCGCATCCGCCAGTCGCAGGAGTGCCCGCGA  
 CTGAGCCGCTCCACCCACTCCACTCTCCAGCCACCACCCACAATCACA  
 AGAAGATTCCCAACCCCTGCCTCCCATGCCTGGTCCCAAGACAGTGAGACA  
 GTCTGGAAGTGATGTGAGATAGCTTCCCAATAAAGCAGCCTCATTCTGA  
 GCCTGAGTGAAAAAAAAAAAAAAAAA  
 >contig\_TCC\_99G12\_RF.fa  
 AGCGGCTATGCAGGTGGTCTGAGCTCGGCCCTATGGGGGCTCACAAGCCC  
 CGGCTCAGCTACAGCTGGGCTCCAGCTTTGGCTCTGGCGCGGGTCCA  
 GCTCCTTCAGCGCGACCCAGCTCCTCCAGGGCGGTGGTGTGAAGAAGATC  
 GAGACACGTGATGGGAGCTGGTGTCTGAGTCCCTGACGCTCCTGCCAA  
 GTGAACAGCTGCGGCGAGCCCTCCAGCCTACCCCTCCTGCGCTGCCCA  
 GAGCTGGGAAGGAGGCGCTATGCAGGTAGCACTGGGAACAGGAGACC  
 CACCTGAGGCTCAGCCCTAGCCCTCAGCCACCTGGGAGTTTACTACCT  
 GGGGACCCCTTGCCCATGCCCTCCAGCTACAAAACAATTCAATTGCTTT  
 TTTTTTTTGGTCCAAATAAACCTCAGTAGCTCTGCCAATGTCAAAA  
 AAAAAAAAAAAAAAAAAA

The first two sequences are from opposite ends of the same polynucleotide, (and  
 are thus in the same gene) . All the other 21 sequences are contigs.

## REFERENCES

AMERICAN CANCER SOCIETY, Estimating new cancer cases and deaths by sex for all sites, Cancer Facts and Figures, pg. 4 (1998)

Burke and Olson, "Preparation of Clone Libraries in Yeast Artificial-Chromosome Vectors" in Methods in Enzymology, Vol. 194, "Guide to Yeast Genetics and Molecular Biology", eds. C. Guthrie and G. Fink, Academic Press, Inc., Chap. 17, pp. 251-270 (1991).

Capecchi, "Altering the genome by homologous recombination" Science 244:1288-1292 (1989).

Cregg JM, Vedvick TS, Raschke WC: Recent Advances in the Expression of Foreign Genes in *Pichia pastoris*, Bio/Technology 11:905-910, 1993

Culver, 1998. Site-Directed recombination for repair of mutations in the human ADA gene. (Abstract) Antisense DNA & RNA based therapeutics, February, 1998, Coronado, CA.

Davies et al., "Targeted alterations in yeast artificial chromosomes for inter-species gene transfer", Nucleic Acids Research, Vol. 20, No. 11, pp. 2693-2698 (1992).

Diatchenko et al., "Suppression subtractive hybridization: A method for generating differentially regulated or tissue-specific cDNA probes and libraries" Proc. Nat Acad. Sci., Vol. 93, pp. 6025-6030 (1996).

Dickinson et al., "High frequency gene targeting using insertional vectors", Human Molecular Genetics, Vol. 2, No. 8, pp. 1299-1302 (1993).

Duff and Lincoln, "Insertion of a pathogenic mutation into a yeast artificial chromosome containing the human APP gene and expression in ES cells", Research Advances in Alzheimer's Disease and Related Disorders, 1995.

Gilboa, E, Eglitis, MA, Kantoff, PW, Anderson, WF: Transfer and expression of cloned genes using retroviral vectors. BioTechniques 4(6):504-512, 1986.

GROSSMAN, HB, Semin. Urol. Oncol., 16(1):17-22 (1998)

HUDSON MA, and HERR HW, Carcinoma *in situ* of the bladder, J. Urol., 153(3, Part 1):564-572 (1995)

HUDSON, MA and HERR HW, Carcinoma *in situ* of the bladder, J. Urol., 153(3) Part 1:564-572 (1995)

Huston et al, 1991 "Protein engineering of single-chain Fv analogs and fusion proteins" in Methods in Enzymology (JJ Langone, ed.; Academic Press, New York, NY) 203:46-88.

Huxley et al., "The human HPRT gene on a yeast artificial chromosome is functional when transferred to mouse cells by cell fusion", Genomics, 9:742-750 (1991).

Jakobovits et al., "Germ-line transmission and expression of a human-derived yeast artificial chromosome", Nature, Vol. 362, pp. 255-261 (1993).

Johnson and Bird, 1991 "Construction of single-chain Fvb derivatives of monoclonal antibodies and their production in *Escherichia coli* in Methods in Enzymology (JJ Langone, ed.; Academic Press, New York, NY) 203:88-99.

LACOMBE L et al., Overexpression of p53 protein in a high-risk population of patients with superficial bladder cancer before and after bacillus Calmette-Guerin therapy; correlation to clinical outcome, J. Urol., 153(3, Part 1):564-572 (1995)

Lamb et al., "Introduction and expression of the 400 kilobase precursor amyloid protein gene in transgenic mice", Nature Genetics, Vol. 5, pp. 22-29 (1993).

Mernaugh and Mernaugh, 1995 "An overview of phage-displayed recombinant antibodies" in Molecular Methods In Plant Pathology (RP Singh and US Singh, eds.; CRC Press Inc., Boca Raton, FL) pp. 359-365.

OZEN H., Curr. Opin. Oncol., 10(3):273-8 (1998)

Pearson and Choi, *Expression of the human  $\beta$ -amyloid precursor protein gene from a yeast artificial chromosome in transgenic mice*. Proc. Natl. Acad. Sci. USA, 1993. 90:10578-82.

Rothstein, "Targeting, disruption, replacement, and allele rescue: integrative DNA transformation in yeast" in Methods in Enzymology, Vol. 194, "Guide to Yeast Genetics and Molecular Biology", eds. C. Guthrie and G. Fink, Academic Press, Inc., Chap. 19, pp. 281-301 (1991).

Schedl et al., "A yeast artificial chromosome covering the tyrosinase gene confers copy number-dependent expression in transgenic mice", Nature, Vol. 362, pp. 258-261 (1993).

Strauss et al., "Germ line transmission of a yeast artificial chromosome spanning the murine  $\alpha_1$  (I) collagen locus", Science, Vol. 259, pp. 1904-1907 (1993).

TORTI FM and LURN BL, The biology and treatment of superficial bladder cancer, J. Clin. Oncol., 2(5):505-531 (1984)